Materials for anchorable protein delivery in bone implants

Ink formulations with bioactive ceramics and polymers for 3D printing create customizable bone scaffolds with tethered proteins, addressing the need for effective tissue regeneration by producing porous and flexible structures for surgical bone replacement.

JP7588136B2Active Publication Date: 2024-11-21THERADAPTIVE INC
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2022508582
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-08-20
Filing Date
2020-08-19
Publication Date
2024-11-21
Estimated Expiration
2040-08-19

AI Technical Summary

Technical Problem

Existing methods for 3D printing of bone scaffolds lack materials that provide both effective bioactivity and mechanical properties necessary for natural tissue regeneration, particularly in customizable and porous structures suitable for surgical bone replacement and transplantation.

Method used

Development of ink formulations incorporating bioactive ceramic materials, such as calcium phosphate and tricalcium phosphate, with polymers like polycaprolactone, that exhibit shear-thinning behavior for extrusion-based 3D printing, allowing for the creation of porous and flexible structures coated with tethered proteins to promote bone growth.

Benefits of technology

The developed inks enable the production of 3D printed structures with precise geometry and enhanced bone regeneration capabilities, suitable for various treatments including bone defects, spinal fusion, and maxillofacial repairs, by providing customizable implants with controlled porosity and flexibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588136000017
    Figure 0007588136000017
  • Figure 0007588136000018
    Figure 0007588136000018
  • Figure 0007588136000019
    Figure 0007588136000019
Patent Text Reader

Abstract

The present disclosure provides devices comprising a therapeutic agent bound to a printed three-dimensional structure. The printed three-dimensional structure comprises about 50% to about 100% by weight of a ceramic and about 0% to about 50% by weight of a polymer. Ink formulations for three-dimensional printing are also disclosed. Additionally, methods for fabricating the devices and uses thereof, for example, in treating a disease in a subject in need thereof, are provided herein.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 889,296, filed Aug. 20, 2019, which is incorporated by reference in its entirety.

[0002] Government Rights This invention was made with Government support under W81XWH-18-C-0182 awarded by the U.S. Army Medical Materiel Command. The Government has certain rights in this invention.

[0003] Sequence Listing This application contains a Sequence Listing, which has been submitted in ASCII format via EFS-Web and is incorporated by reference in its entirety. The ASCII copy created on August 13, 2020 is named 50222-703.601_SEQ.txt and is 235KB in size. [Background technology]

[0004] Three-dimensional (3D) printing is a manufacturing process that creates three-dimensional solid objects from digital files. In additive methods of 3D printing, objects are created by laying down successive layers of material until the desired object is created, with up to micrometer precision. Combined with computer-aided design (CAD) software, 3D printing allows for the generation of complex functional shapes that can be easily customized compared to traditional manufacturing methods.

[0005] Surgical implantation of scaffolds and / or other forms of graft materials to promote tissue regeneration is a useful technique when the implant can match the mechanical properties of native tissue. A variety of materials, including materials that mimic tissue and allow tissue regrowth, can be used as inks in the fabrication of porous 3D printed structures for implantation. Inks with effective bioactivity and mechanical properties are necessary for the regeneration of native tissue and can be customized for use in 3D printing and employed in the repair of large tissue defects. Summary of the Invention

[0006] Various ink formulations have been developed incorporating bioactive ceramic materials for 3D printing of porous bone scaffold implants. These inks are formulated by dispersing ceramic particles in liquid ink components using a dual asymmetric centrifugal mixing process. Scaffolds printed with these inks are then coated with tethered proteins that promote bone growth. The 3D printed materials can be seeded with cells and used for surgical bone replacement and implantation. The first of the inks developed allows for the 3D printing of robust calcium phosphate ceramic materials, the second allows for the 3D printing of flexible and easy to handle calcium phosphate polymer composites, and the third allows for the 3D printing of blends containing tricalcium phosphate powders, water-insoluble polymers, and water-soluble polymers that produce porous and flexible prints. The ink formulations have shear-thinning behavior that allows for 3D printing by extrusion-based techniques such as Direct Ink Writing (also known as robocasting) and melt extrusion.

[0007] Both techniques are methods of additive manufacturing in which a filament of paste (called "ink") is extruded (e.g., from a syringe) through a small nozzle while the nozzle moves across a build platform. A 3D computer-aided design (CAD) model of the object to be printed is divided into layers of thickness similar to the nozzle diameter. The object is produced by extruding a filament of ink in the shape required to fill the first layer. The build platform is then moved down or the nozzle is moved (e.g., by the width of the nozzle diameter) and the next layer is deposited in the pattern required by the subsequent layer. This process is repeated until the fabrication of the 3D object is complete.

[0008] In robocasting, the position of the nozzle is controlled to trace the shape of each layer, so that the ink (typically a ceramic slurry) emerges from the nozzle in a liquid-like state, but immediately retains its shape due to the shear-thinning rheological properties of the ink. The desired object can be built up in this way, layer by layer, to produce geometrically complex ceramic bodies.

[0009] During melt extrusion, the ink material is heated above the polymer melt temperature within the 3D printer so that it can be extruded through the nozzle. After the polymer leaves the printing nozzle, it rapidly cools and hardens so that subsequent layers can be applied to create a three-dimensional object.

[0010] An embodiment of the present disclosure is a device that includes a therapeutic agent non-covalently bound to a printed three-dimensional structure, the printed three-dimensional structure including about 50% to about 100% by weight ceramic and about 0% to about 50% by weight polymer.

[0011] In some embodiments, the three-dimensional structure has a mass of about 1 g / cm 3 and about 3g / cm 3 between about 15% and about 45% open porosity, and about 0.50m 2 / g and about 1.0m 2 / g and the three-dimensional structure has a fiber diameter of about 325 μm and about 475 μm.

[0012] In various embodiments, the ceramic comprises calcium phosphate, hydroxyapatite, fluorapatite, bone, silicate, or vanadate, or a combination thereof.

[0013] In an embodiment, the ceramic comprises β-tricalcium phosphate (β-TCP).

[0014] In some embodiments, the polymer comprises polycaprolactone.

[0015] In various embodiments, the device comprises about 100% by weight ceramic, in which the ceramic comprises β-tricalcium phosphate (β-TCP).

[0016] In an embodiment, the device comprises about 70% to about 80% by weight ceramic and about 20% to about 30% by weight polymer, in which the ceramic can comprise β-tricalcium phosphate (β-TCP) and the polymer comprises polycaprolactone.

[0017] The printed three-dimensional structures may be formed from an ink comprising about 30% to about 70% by weight ceramic, about 5% to about 30% by weight polymer, and optionally an antifoaming agent and / or a dispersing agent.

[0018] In some embodiments, the therapeutic agent comprises a mammalian growth factor or a functional portion thereof.

[0019] In various embodiments, the therapeutic agent comprises one or more polypeptides selected from Table 4, or a functional portion thereof.

[0020] In embodiments, the therapeutic agent comprises a bone morphogenetic protein (BMP).

[0021] The therapeutic agent may include a targeting moiety, and the targeting moiety is non-covalently bound to the printed three-dimensional structure. In the device, the targeting moiety may be bound to the printed three-dimensional structure with an affinity of about 1 pM to about 100 μm. The targeting moiety comprises a polypeptide that is at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to any one of the sequences in Tables 5-6. In the device, the targeting moiety selected from the sequences in Tables 5-6 may include about 2, 3, 4, 5, 6, 7, 8, 9, or 10 sequences.

[0022] In various embodiments, the Therapeutic Agent is a chimeric polypeptide comprising a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs:794-802.

[0023] Another aspect of the present disclosure is a method of treating a disease in a subject in need thereof, comprising administering to the subject any of the devices disclosed herein.

[0024] In some embodiments, the disease comprises a bone defect, a cartilage defect, a soft tissue defect, a tendon defect, a fascial defect, a ligament defect, an organ defect, an osteotendinous tissue defect, a skin defect, an osteochondral defect, osteoporosis, avascular necrosis, or a congenital skeletal deformity, or a combination thereof.

[0025] In embodiments, the method includes spinal fusion, which may include posterior lumbar fusion (PLF) and / or interbody fusion.

[0026] In various embodiments, the method includes bone repair, dental repair, craniomaxillofacial repair, ankle fusion, vertebroplasty, osteoplasty, navicular fracture repair, tendeno-osseous repair, rib reconstruction, subchondral bone repair, cartilage repair, or surgical implantation of a three-dimensional structure or device, or a combination thereof.

[0027] However, another aspect is a method for producing a three-dimensional structure, the method comprising the steps of providing a solution comprising a ceramic, a polymer, and optionally an antifoaming agent and / or a dispersant, mixing the solution to obtain an ink formulation, and depositing the ink formulation in a three-dimensional form. The method comprises (i) an ink formulation comprising about 30% to about 70% by weight of a ceramic and about 5% to about 60% by weight of a polymer, and / or (ii) a three-dimensional structure comprising about 50% to about 100% by weight of a ceramic and about 0% to about 50% by weight of a polymer.

[0028] In some embodiments, the ink formulation and / or the ceramic of the three-dimensional structure comprises calcium phosphate, hydroxyapatite, fluorapatite, bone, silicate, or vanadate, or a combination thereof.

[0029] In embodiments, the ink formulation and / or the three-dimensional structural ceramic comprises β-tricalcium phosphate (β-TCP).

[0030] In various embodiments, the polymer of the ink formulation comprises a first polymer comprising polycaprolactone and a second polymer comprising polyethylene glycol. In the method, the ink formulation may comprise from about 10% to about 30% by weight of polycaprolactone and from about 10% to about 30% by weight of polyethylene glycol.

[0031] The three-dimensional structure may comprise about 100% by weight ceramic.

[0032] In some embodiments, the three-dimensional structure comprises about 100% by weight β-tricalcium phosphate (β-TCP).

[0033] In various embodiments, the three-dimensional structure comprises about 70% to about 80% by weight ceramic and about 20% to about 30% by weight polymer.

[0034] The three-dimensional structure can include about 70% to about 80% by weight β-tricalcium phosphate (β-TCP) and about 20% to about 30% by weight polycaprolactone.

[0035] In embodiments, the method further comprises combining the three-dimensional structure with a therapeutic agent, wherein the therapeutic agent comprises a mammalian growth factor or functional portion thereof, and / or one or more polypeptides or functional portions thereof selected from Table 4. The therapeutic agent may comprise a bone morphogenetic protein (BMP).

[0036] In some embodiments, the therapeutic agent comprises a targeting moiety that is non-covalently bound to the three-dimensional structure. In the method, the targeting moiety can bind to the printed three-dimensional structure with an affinity of about 1 pM to about 100 μm.

[0037] The targeting moiety comprises a polypeptide that is at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to any one of the sequences in Tables 5-6.

[0038] In various embodiments, the targeting moiety comprises about 2, 3, 4, 5, 6, 7, 8, 9, or 10 sequences selected from the sequences in Tables 5-6.

[0039] In embodiments, the Therapeutic Agent is a chimeric polypeptide comprising a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs:794-802.

[0040] In one aspect, the present disclosure provides a method for treating a disease in a subject in need thereof, comprising administering to the subject any of the three-dimensional structures disclosed herein.

[0041] In some embodiments, the disease comprises a bone defect, a cartilage defect, a soft tissue defect, a tendon defect, a fascial defect, a ligament defect, an organ defect, an osteotendinous tissue defect, a skin defect, an osteochondral defect, osteoporosis, avascular necrosis, or a congenital skeletal deformity, or a combination thereof.

[0042] The method may include spinal fusion, hi various embodiments, the spinal fusion includes posterolateral fusion (PLF) and / or interbody fusion.

[0043] In embodiments, the method includes bone repair, dental repair, craniomaxillofacial repair, ankle fusion, vertebroplasty, osteoplasty, navicular fracture repair, tendon-bone repair, rib reconstruction, subchondral bone repair, cartilage repair, or surgical implantation of a three-dimensional structure or device, or a combination thereof.

[0044] In another aspect, the present disclosure provides an ink formulation for three dimensional printing, the ink formulation comprising about 30% to about 70% by weight of a ceramic and about 5% to about 30% by weight of a polymer.

[0045] In some embodiments, the ceramic comprises calcium phosphate, hydroxyapatite, fluorapatite, bone, silicate, or vanadate, or a combination thereof.

[0046] In an embodiment, the ceramic comprises β-tricalcium phosphate (β-TCP).

[0047] The formulation comprises about 50% to about 70% by weight of a ceramic, about 10% to about 30% by weight of a first polymer, and about 10% to about 30% by weight of a second polymer, or about 50% to about 70% by weight of β-tricalcium phosphate (β-TCP), about 10% to about 30% by weight of a first polymer comprising polycaprolactone, and about 10% to about 30% by weight of a second polymer comprising polyethylene glycol.

[0048] In various embodiments, the formulation comprises about 50% to about 70% by weight ceramic, about 5% to about 15% by weight polymer, and optionally an antifoaming agent and / or dispersing agent, or about 50% to about 70% by weight tricalcium phosphate, about 5% to about 15% by weight poloxamer, and optionally an antifoaming agent and / or dispersing agent. The formulation may comprise about 0.1% to about 1% by weight antifoaming agent, where the antifoaming agent comprises an alcohol, and / or about 0.1% to about 1% by weight dispersing agent, where the dispersing agent optionally comprises an ammonium polyacrylate.

[0049] The formulation may comprise about 40% to about 60% by weight of ceramic, about 5% to about 15% by weight of polymer, and about 30% to about 40% by weight of solvent, or about 40% to about 60% by weight of β-tricalcium phosphate (β-TCP), about 5% to about 15% by weight of polycaprolactone, and about 30% to about 40% by weight of solvent. In embodiments, the solvent comprises dichloromethane, 2-butoxyethanol, dibutyl phthalate, or chloroform, or a combination thereof.

[0050] In a further aspect, the present disclosure provides a method for preparing a three-dimensional structure, comprising using any of the formulations disclosed herein as an ink in a three-dimensional printing process.

[0051] An aspect of the present disclosure is a three-dimensional structure prepared using any of the formulations disclosed herein.

[0052] In various embodiments, the three-dimensional structure comprises about 50% to about 100% ceramic by weight.

[0053] In some embodiments, the three-dimensional structure comprises about 50% to about 100% tricalcium phosphate by weight.

[0054] In embodiments, the three-dimensional structure comprises about 50% to about 90% by weight tricalcium phosphate and about 10% to about 50% polymer, which may include polycaprolactone.

[0055] The three-dimensional structure is approximately 1g / cm 3 and about 3g / cm 3 between about 15% and about 45% open porosity, and about 0.50m 2 / g and about 1.0m 2 / g, and the three-dimensional structure has a fiber diameter of about 325 μm and about 475 μm.

[0056] Another aspect of the present disclosure is a three-dimensional structure that includes about 50% to about 100% by weight ceramic and about 0% to about 50% polymer.

[0057] In some embodiments, the ceramic comprises calcium phosphate, hydroxyapatite, fluorapatite, bone, silicate, or vanadate, or a combination thereof.

[0058] In an embodiment, the ceramic comprises β-tricalcium phosphate (β-TCP).

[0059] In some embodiments, the three-dimensional structure comprises about 50% to about 100% ceramic by weight.

[0060] In various embodiments, the three-dimensional structure comprises about 100% ceramic by weight.

[0061] In a further embodiment, the three-dimensional structure comprises about 100% by weight tricalcium phosphate.

[0062] The three-dimensional structure may comprise about 50% to about 90% by weight ceramic and about 10% to about 50% polymer, or about 50% to about 90% by weight tricalcium phosphate and about 10% to about 50% polymer. In an embodiment, the polymer comprises polycaprolactone.

[0063] In an embodiment, the three-dimensional structure has a density of about 1 g / cm 3 and about 3g / cm 3 between about 15% and about 45% open porosity, and about 0.50m 2 / g and about 1.0m 2 / g and the three-dimensional structure has a fiber diameter of about 325 μm and about 475 μm.

[0064] Three-dimensional structures can be prepared by three-dimensional printing methods.

[0065] A further aspect of the present disclosure is a method for delivering a therapeutic agent to a subject in need thereof, comprising delivering to an organ or tissue of the subject a device comprising the therapeutic agent and any of the three-dimensional structures disclosed herein.

[0066] In one aspect, the present disclosure provides a device comprising a therapeutic agent and any of the three-dimensional structures disclosed herein.

[0067] In various embodiments, the therapeutic agent comprises a mammalian growth factor or a functional portion thereof.

[0068] In embodiments, the Therapeutic Agent comprises one or more polypeptides selected from Table 4, or a functional portion thereof.

[0069] In some embodiments, the therapeutic agent comprises a bone morphogenetic protein (BMP).

[0070] The device may include a targeting moiety. In embodiments, the targeting moiety includes a polypeptide that includes one or more sequences that are at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to any one of the sequences in Tables 5-6. The targeting moiety may include about 2, 3, 4, 5, 6, 7, 8, 9, or 10 sequences selected from the sequences in Tables 5-6. In some embodiments, the targeting moiety is non-covalently bound to the three-dimensional structure.

[0071] In various embodiments, the targeting moiety is linked to the therapeutic agent in the chimeric polypeptide.

[0072] In some embodiments, the chimeric polypeptide comprises a sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs:794-802.

[0073] In another aspect, the disclosure provides a method of preparing any of the devices disclosed herein, comprising combining a therapeutic agent with a three-dimensional structure, wherein the therapeutic agent is non-covalently bound to the three-dimensional structure.

[0074] In yet another aspect, the present disclosure provides a method for treating a disease in a subject in need thereof, comprising administering to the subject any of the three-dimensional structures disclosed herein or any of the devices disclosed herein.

[0075] In various embodiments, the disease comprises a bone defect, a cartilage defect, a soft tissue defect, a tendon defect, a fascial defect, a ligament defect, an organ defect, an osteotendinous tissue defect, a skin defect, an osteochondral defect, osteoporosis, avascular necrosis, or a congenital skeletal deformity, or a combination thereof. The method may include spinal fusion, including, for example, posterolateral fusion (PLF) and / or interbody fusion.

[0076] In some embodiments, the method comprises bone repair, dental repair, craniomaxillofacial repair, ankle fusion, vertebroplasty, osteoplasty, navicular fracture repair, tendon-bone repair, rib reconstruction, subchondral bone repair, cartilage repair, or surgical implantation of a three-dimensional structure or device, or a combination thereof.

[0077] In aspects or embodiments disclosed herein, the three-dimensional structure has a mass of about 1 g / cm 3 and about 3g / cm 3 The density may be between 0.01 and 0.1.

[0078] In aspects or embodiments disclosed herein, the three-dimensional structure may have an open porosity of between about 15% and about 45%.

[0079] In aspects or embodiments disclosed herein, the three-dimensional structure is about 0.50 mm 2 / g and about 1.0m 2 / g.

[0080] In aspects or embodiments disclosed herein, the three-dimensional structures may have fiber diameters of about 325 μm and about 475 μm.

[0081] In aspects or embodiments disclosed herein, the three-dimensional structure has a mass of about 1 g / cm 3 and about 3g / cm 3 between about 15% and about 45% open porosity, and about 0.50m 2 / g and about 1.0m 2 / g, and the three-dimensional structure has a fiber diameter of about 325 μm and about 475 μm.

[0082] In an embodiment, the three-dimensional structure has a density of about 2.44 g / cm 3 It has a density of about 1.0, an open porosity of about 19.6%, and a fiber diameter of about 384 μm.

[0083] In another embodiment, the three-dimensional structure has a mass of about 1.32 g / cm 3 It has a density of about 100%, an open porosity of about 38%, and a fiber diameter of about 394 μm.

[0084] In yet another embodiment, the three-dimensional structure has a mass of about 1.49 g / cm 3 density, approximately 31% open porosity, 0.81m 2 / g, and a fiber diameter of 420 μm.

[0085] Advantages of the materials and methods described herein include providing 3D printed customizable implants and more universal piece, block, or cylindrical objects. When implants are 3D printed, precise control of the implant geometry is possible. Thus, implants printed with these inks are suitable for a variety of treatments including long bone repair, spinal fusion, maxillofacial structures, and more. To enhance bone tissue regeneration, the ceramic inclusions of the implantable device can be loaded with anchorable growth factors. Different formulations of the inks produce materials that result in implantable devices with different properties, including different porosity and flexibility.

[0086] The details of one or more embodiments of the disclosure are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the disclosure will become apparent from the description, drawings, and claims. [Brief description of the drawings]

[0087] [Figure 1A] An overview of the process for producing 3D printed objects using calcium phosphate ceramic ink. [Figure 1B] FIG. 1B is a flow chart illustrating the steps for making the calcium phosphate ceramic ink used in FIG. 1A. [Figure 2A] An overview of the process for fabricating 3D printed objects using calcium phosphate polymer ink. [Figure 2B] FIG. 2B is a flow chart illustrating the steps for making the calcium phosphate polymer ink used in FIG. 2A. [Figure 2C] FIG. 2B is a micrograph of an exemplary 3D printed object made with a calcium phosphate polymer ink as outlined in FIG. 2A. [Figure 3A] An overview of the process for producing 3D printed objects using composite inks. [Figure 3B] 3B is a flow chart illustrating the steps for making the composite ink used in FIG. 3A. [Figure 3C] FIG. 2B is an exemplary micrograph of a 3D printed sample made with the composite ink as outlined in FIG. 2A. [Figure 4A] 1 is a photograph of an exemplary 3D printed object made with a composite ink (320) as described herein. [Figure 4B] FIG. 4B is a photograph of the 3D printed object of FIG. 4A prior to hydration. [Figure 4C] 4B is a photograph of the 3D printed object of FIG. 4A hydrated with arterial blood. [Figure 4D] FIG. 4D is a photograph of the 3D printed object of FIG. 4C ready for implantation.

[0088] Like reference symbols in the various drawings indicate like elements. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0089] Various calcium phosphate ceramic ink formulations have been developed for 3D printing of porous bone scaffold implants. The ink formulations have shear-thinning behavior that allows 3D printing by extrusion-based techniques. These inks are formulated by dispersing ceramic particles in liquid ink components using a dual asymmetric centrifugal mixing process. The first such ink 3D prints a robust calcium phosphate ceramic material, the second 3D prints a flexible and easy-to-handle calcium phosphate polymer composite, and the third 3D prints structures via melt extrusion that contain β-TCP powder, a water-soluble polymer, and a blend of the porous and flexible water-soluble polymer.

[0090] The 3D printed structures described herein are coated with anchorable proteins (e.g., tBMP2) during fabrication that promote bone growth. In some instances, cells can be seeded onto the 3D printed structures after fabrication so that the cells occupy the pores of the 3D printed structures. Once prepared, the 3D printed structures can be surgically implanted into patients for surgical bone replacement and grafting.

[0091] Ink formulation In one aspect, a formulation for fabricating 3D printed structures is provided herein.As non-limiting examples, the formulation includes ceramic materials, such as calcium phosphates (e.g., tricalcium phosphate, β-tricalcium phosphate, α-tricalcium phosphate), hydroxyapatite, fluorapatite, bone (e.g., demineralized bone), glass (bioglass), such as silicate, vanadate, and related ceramic minerals, or chelated divalent metal ions, or combinations thereof.In some embodiments, the ceramic material includes β-tricalcium phosphate (β-TCP). In some embodiments, the formulation is about 30-70, 30-65, 30-60, 30-55, 30-50, 30-45, 30-40, 30-35, 35-70, 35-65, 35-60, 35-55, 35-50, 35-45, 35-40, 40-70, 40-65, 40-60, 40-55, 40-50, 40-45, 45-70, 45-65, 45-60, 45-55, 45-50, 50-70, 50-65, 50-55, 55-70, 55-65, 55-60, 60-70, 60-65, or 65-70 weight percent ceramic of the formulation. For example, the above formulation is about 30% by weight, 31% by weight, 32% by weight, 33% by weight, 34% by weight, 35% by weight, 36% by weight, 37% by weight, 38% by weight, 39% by weight, 40% by weight, 41% by weight, 42% by weight, 43% by weight, 44% by weight, 45% by weight, 46% by weight, 47% by weight, 48% by weight, 49% by weight, 50% by weight, 51% by weight, 52% by weight, 53% by weight, 54% by weight, 55% by weight, 56% by weight, 57% by weight, 58% by weight, 59% by weight, 60% by weight, 61% by weight, 62% by weight, 63% by weight, 64% by weight, 65% by weight, 66% by weight, 67% by weight, 68% by weight, 69% by weight, or 70% by weight. In some embodiments, the ceramic is β-TCP. In some embodiments, the β-TCP is introduced into the formulation as a powder. In some embodiments, the formulation comprises one or more additional ingredients, non-limiting examples of which include water, polymers, antifoam agents, dispersants, solvents, and plasticizers.

[0092] In some embodiments, the formulation comprises one or more polymers, for example, about 1, 2, 3, 4, or 5 polymers. Non-limiting examples of polymers include poly(ethylene oxide), poly(propylene oxide), polyethylene glycol (PEG), and polyester. In some embodiments, the formulation is about 5-30 weight percent polymer. In some embodiments, the formulation is about 5-30, 5-25, 5-20, 5-15, 5-10, 10-30, 10-25, 10-20, 10-15, 15-30, 15-25, 15-20, 20-30, 20-25, or 25-30 weight percent of the first polymer and about 5-30 weight percent of the second polymer. In one example, the polymer comprises a poloxamer. Poloxamers are block copolymers of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO). A non-limiting example of a poloxamer is poloxamer 407, such as Pluronic® F-127. In some embodiments, the formulation comprises about 5-20, 5-15, 5-10, 10-20, 10-15, or 15-20 weight percent of poloxamer (407). As another example, the polymer comprises polyethylene glycol (PEG). In some embodiments, the formulation comprises about 10-30, 10-25, 10-20, 10-15, 15-30, 15-25, 15-20, 20-30, 20-25, or 25-30 weight percent of PEG. In some embodiments, the formulation comprises a PEG having a molecular weight of 1,500 g / mol. As another example, the polymer comprises a polyester. In some embodiments, the polyester is a biodegradable polyester, such as polycaprolactone (PCL). In some cases, the formulation includes about 10-30, 10-25, 10-20, 10-15, 15-30, 15-25, 15-20, 20-30, 20-25, or 25-30 weight percent PCL. In some cases, the formulation includes PCL having a molecular weight of 50,000 g / mol.

[0093] In some embodiments, the formulation includes one or more antifoaming agents, for example, about 1, 2, or 3 antifoaming agents. Non-limiting examples of antifoaming agents include 1-ocatanol, 2-butoxyethanol, oleic acid, sulfonated oils, organic phosphates, and dimethylpolysiloxanes. In some embodiments, the antifoaming agent includes an octanol, such as 1-octanol. In some cases, the formulation includes an antifoaming agent of about 0.25-0.75, 0.25-0.70, 0.25-0.65, 0.25-0.60, 0.25-0.55, 0.25-0.50, 0.25-0.45, 0.25-0.40, 0.25-0.35, 0.25-0.30, 0.30-0.75, 0.30-0.70, 0.30-0.65, 0.30~0.60, 0.30~0.55, 0.30~0.50, 0.30~0.45, 0.30~0.40, 0.30~0.35, 0.35~0.75, 0.35~0.70, 0.35~0.65, 0.35~0.60, 0.35~0.55, 0.35~0.50, 0.35~0.45, 0.35~0.40, 0.40 ~0.75, 0.40~0.70, 0.40~0.65, 0.40~0.60, 0.40~0.55, 0.40~.50, 0.40~0.45, 0.45~0.75, 0.45~0.70, 0.45~0.65, 0.45~0.60, 0.45~0.55, 0.45~0.50, 0.50~0.75, 0.50~0.7 The formulation comprises 0, 0.50-0.65, 0.50-0.60, 0.50-0.55, 0.55-0.75, 0.55-0.70, 0.55-0.65, 0.55-0.60, 0.60-0.75, 0.60-0.70, 0.60-0.65, 0.65-0.75, or 0.65-0.70 weight percent 1-octanol. In some embodiments, the antifoam agent comprises 2-butoxyethanol. In some cases, the formulation comprises about 2.5-12.5, 2.5-10, 2.5-7.5, 2.5-5, 5-12.5, 5-10, 5-7.5, 7.5-12.5, 7.5-10, or 10-12.5 weight percent 2-butoxyethanol.

[0094] In some embodiments, the formulation includes one or more dispersants, for example, about 1, 2, or 3 dispersants. Non-limiting examples of dispersants include Darvan® 821-A, Darvan® CN, Darvan® 811, Darvan® 811D, Darvan® 7N, and Darvan® 7-NS. In some cases, the formulation includes about 0.1-0.3, 0.1-0.25, 0.1-0.2, 0.1-0.15, 0.15-0.3, 0.15-0.25, 0.15-0.2, 0.2-0.3, 0.2-0.25, or 0.25-0.3 weight percent of dispersant. In some embodiments, the dispersant includes Darvan® 821-A.

[0095] In some embodiments, the formulation includes one or more solvents, for example, about 1, 2, or 3 solvents. In some cases, the formulation includes about 25-35, 25-33, 25-31, 25-29, 25-27, 27-33, 27-31, 27-29, 29-35, 29-33, 29-31, 31-35, or 33-35 weight percent of the solvent. Exemplary solvents include organochlorides, such as dichloromethane (DCM) and chloroform, and the solvent can be 2-butoxyethanol. In some cases, the solvent combination can include dibutyl phthalate.

[0096] In some embodiments, the formulation includes one or more plasticizers, for example, about 1, 2, or 3 plasticizers. In some cases, the formulation includes about 2-6, 2-5, 2-4, 2-3, 3-6, 3-5, 3-4, 4-6, or 5-6 weight percent of the plasticizer. In some embodiments, the plasticizer includes a phthalate. Non-limiting examples of phthalates include dibutyl phthalate (DBP), benzyl butyl diphthalate (BBP), and diethylhexyl-phthalate (DEHP).

[0097] In some embodiments, the formulation comprises β-TCP and a polymer. The polymer comprises PEO, PPO, PEG, or polyester, or a combination thereof. In some embodiments, the formulation comprises about 30-70, 30-65, 30-60, 30-55, 30-50, 30-45, 30-40, 30-35, 35-70, 35-65, 35-60, 35-55, 35-50, 35-45, 35-40, 40-70, 40-65, 40-60, 40-55, 40-50, 40-45, 45-70, 45-65, 45-60, 45-55, 45-50, 50-70, 50-65, 50-60, 50-55, 55-70, 55-65, 55-60, 60-70, 60-65, or 65-70 weight percent β-TCP, e.g., about 30 weight%, 31 weight%, 32 weight%, 33 weight%, 34 weight%, 35 weight%, 36 weight%, 37 weight%, 38 weight%, 39 weight%, 40 weight%, 41 weight%, 42 weight%, 43 weight%, 44 weight%, 45 weight%, 46 weight%, 47 weight%, 48 weight%, 49 weight%, 50 weight%, 51 weight%, 52 weight%, 53 weight% 54% 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70% by weight of β-TCP. In some cases, the formulation includes about 5-20, 5-15, 5-10, 10-20, 10-15, or 15-20 weight percent of poloxamer 407. In some cases, the formulation includes about 10-30, 10-25, 10-20, 10-15, 15-30, 15-25, 15-20, 20-30, 20-25, or 25-30 weight percent of PEG. In some cases, the formulation comprises about 10-30, 10-25, 10-20, 10-15, 15-30, 15-25, 15-20, 20-30, 20-25, or 25-30 weight percent PCL. In some embodiments, the formulation further comprises an antifoaming agent. In some embodiments, the formulation further comprises a dispersing agent. In some embodiments, the formulation further comprises a solvent. In some embodiments, the formulation further comprises a plasticizer.

[0098] In some embodiments, the formulation comprises β-TCP and an antifoaming agent. The antifoaming agent may comprise 1-octanol and / or 2-butoxyethanol. In some embodiments, the formulation comprises about 30-70, 30-65, 30-60, 30-55, 30-50, 30-45, 30-40, 30-35, 35-70, 35-65, 35-60, 35-55, 35-50, 35-45, 35-40, 40-70, 40-65, 40-60, 40-55, 40-50, 40-45, 45-70, 45-65, 45-60, 45-55, 45-50, 50-70, 50-65, 50-60, 50-55, 5 5 to 70, 55 to 65, 55 to 60, 60 to 70, 60 to 65, or 65 to 70 weight percent β-TCP, e.g., about 30 weight%, 31 weight%, 32 weight%, 33 weight%, 34 weight%, 35 weight%, 36 weight%, 37 weight%, 38 weight%, 39 weight%, 40 weight%, 41 weight%, 42 weight%, 43 weight%, 44 weight%, 45 weight%, 46 weight%, 47 weight%, 48 weight%, 49 weight%, 50 weight%, 51 weight%, 52 weight%, 53 weight% 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70% β-TCP by weight.In some cases, the formulation may comprise a concentration of about 0.25-0.75, 0.25-0.70, 0.25-0.65, 0.25-0.60, 0.25-0.55, 0.25-0.50, 0.25-0.45, 0.25-0.40, 0.25-0.35, 0.25-0.30, 0.30-0.75, 0.30-0.70, 0.30-0.65, 0.30~0.60, 0.30~0.55, 0.30~0.50, 0.30~0.45, 0.30~0.40, 0.30~0.35, 0.35~0.75, 0.35~0.70, 0.35~0.65, 0.35~0.60, 0.35~0.55, 0.35~0.50, 0.35~0.45, 0.35~0.40, 0.40 ~0.75, 0.40~0.70, 0.40~0.65, 0.40~0.60, 0.40~0.55, 0.40~.50, 0.40~0.45, 0.45~0.75, 0.45~0.70, 0.45~0.65, 0.45~0.60, 0.45~0.55, 0.45~0.50, 0.50~0.75, 0.50~0.7 The formulation may comprise 0, 0.50-0.65, 0.50-0.60, 0.50-0.55, 0.55-0.75, 0.55-0.70, 0.55-0.65, 0.55-0.60, 0.60-0.75, 0.60-0.70, 0.60-0.65, 0.65-0.75, or 0.65-0.70 weight percent 1-octanol. In some cases, the formulation comprises about 2.5-12.5, 2.5-10, 2.5-7.5, 2.5-5, 5-12.5, 5-10, 5-7.5, 7.5-12.5, 7.5-10, or 10-12.5 weight percent 2-butoxyethanol. In some embodiments, the formulation further comprises a polymer. In some embodiments, the formulation further comprises a dispersing agent. In some embodiments, the formulation further comprises a solvent, hi some embodiments, the formulation further comprises a plasticizer.

[0099] In some embodiments, the formulation comprises β-TCP and a dispersing agent. Non-limiting examples of dispersing agents include Darvan® 821-A, Darvan® CN, Darvan® 811, Darvan® 811D, Darvan® 7N, and Darvan® 7-NS. The dispersing agent can include Darvan® 821-A. In some embodiments, the formulation comprises about 30-70, 30-65, 30-60, 30-55, 30-50, 30-45, 30-40, 30-35, 35-70, 35-65, 35-60, 35-55, 35-50, 35-45, 35-40, 40-70, 40-65, 40-60, 40-55, 40-50, 40-45, 45-70, 45-65, 45-60, 45-55, 45-50, 50-70, 50-65, 50-60, 50-55, 5 5 to 70, 55 to 65, 55 to 60, 60 to 70, 60 to 65, or 65 to 70 weight percent β-TCP, e.g., about 30 weight%, 31 weight%, 32 weight%, 33 weight%, 34 weight%, 35 weight%, 36 weight%, 37 weight%, 38 weight%, 39 weight%, 40 weight%, 41 weight%, 42 weight%, 43 weight%, 44 weight%, 45 weight%, 46 weight%, 47 weight%, 48 weight%, 49 weight%, 50 weight%, 51 weight%, 52 weight%, 53 weight% 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70% by weight of β-TCP. In some cases, the formulation comprises about 0.1-0.3, 0.1-0.25, 0.1-0.2, 0.1-0.15, 0.15-0.3, 0.15-0.25, 0.15-0.2, 0.2-0.3, 0.2-0.25, or 0.25-0.3 weight percent of a dispersant. In some embodiments, the formulation further comprises a polymer. In some embodiments, the formulation further comprises a solvent. In some embodiments, the formulation further comprises a plasticizer. In some embodiments, the formulation further comprises an antifoaming agent.

[0100] In some embodiments, the formulation comprises β-TCP and an extractant. The solvent can comprise an organic chlorine, such as dichloromethane (DCM) and chloroform, and the solvent can be 2-butoxyethanol. The combination of solvents can comprise dibutyl phthalate. In some embodiments, the formulation comprises about 30-70, 30-65, 30-60, 30-55, 30-50, 30-45, 30-40, 30-35, 35-70, 35-65, 35-60, 35-55, 35-50, 35-45, 35-40, 40-70, 40-65, 40-60, 40-55, 40-50, 40-45, 45-70, 45-65, 45-60, 45-55, 45-50, 50-70, 50-65, 50-60, 50-55, 5 5 to 70, 55 to 65, 55 to 60, 60 to 70, 60 to 65, or 65 to 70 weight percent β-TCP, e.g., about 30 weight%, 31 weight%, 32 weight%, 33 weight%, 34 weight%, 35 weight%, 36 weight%, 37 weight%, 38 weight%, 39 weight%, 40 weight%, 41 weight%, 42 weight%, 43 weight%, 44 weight%, 45 weight%, 46 weight%, 47 weight%, 48 weight%, 49 weight%, 50 weight%, 51 weight%, 52 weight%, 53 weight% 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70% by weight of β-TCP. In some cases, the formulation comprises about 25-35, 25-33, 25-31, 25-29, 25-27, 27-33, 27-31, 27-29, 29-35, 29-33, 29-31, 31-35, or 33-35 weight percent of a solvent. In some embodiments, the formulation further comprises a polymer. In some embodiments, the formulation further comprises a dispersing agent. In some embodiments, the formulation further comprises a plasticizer. In some embodiments, the formulation further comprises an antifoaming agent.

[0101] In some embodiments, the formulation comprises β-TCP and a plasticizer. The solvent may comprise a phthalate. Non-limiting examples of phthalates include dibutyl phthalate (DBP), benzyl butyl diphthalate (BBP), and diethylhexyl-phthalate (DEHP). In some embodiments, the formulation comprises about 30-70, 30-65, 30-60, 30-55, 30-50, 30-45, 30-40, 30-35, 35-70, 35-65, 35-60, 35-55, 35-50, 35-45, 35-40, 40-70, 40-65, 40-60, 40-55, 40-50, 40-45, 45-70, 45-65, 45-60, 45-55, 45-50, 50-70, 50-65, 50-60, 50-55, 5 5 to 70, 55 to 65, 55 to 60, 60 to 70, 60 to 65, or 65 to 70 weight percent β-TCP, e.g., about 30 weight%, 31 weight%, 32 weight%, 33 weight%, 34 weight%, 35 weight%, 36 weight%, 37 weight%, 38 weight%, 39 weight%, 40 weight%, 41 weight%, 42 weight%, 43 weight%, 44 weight%, 45 weight%, 46 weight%, 47 weight%, 48 weight%, 49 weight%, 50 weight%, 51 weight%, 52 weight%, 53 weight% 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70% by weight of β-TCP. In some cases, the formulation comprises about 25-35, 25-33, 25-31, 25-29, 25-27, 27-33, 27-31, 27-29, 29-35, 29-33, 29-31, 31-35, or 33-35 weight percent of a solvent. In some cases, the formulation comprises about 2-6, 2-5, 2-4, 2-3, 3-6, 3-5, 3-4, 4-6, or 5-6 weight percent of a plasticizer. In some embodiments, the formulation further comprises a polymer. In some embodiments, the formulation further comprises a dispersant. In some embodiments, the formulation further comprises a solvent. In some embodiments, the formulation further comprises an antifoaming agent.

[0102] In one embodiment, the formulation comprises about 45% to about 65% β-TCP. For example, the formulation comprises about 45-60, 45-55, 45-50, 50-65, 50-60, 50-55, 55-65, 55-60, 60-65, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, or 65 weight percent β-TCP. In some embodiments, the formulation comprises water, e.g., about 20-40, 20-35, 20-30, 20-25, 25-40, 25-35, 25-30, 30-40, 30-35, or 35-40 weight percent water. In some embodiments, the formulation includes a polymer, e.g., about 5-20, 5-15, 5-10, 10-20, 10-15, or 15-20 weight percent of a polymer. The polymer can be a poloxamer, such as Poloxamer 407. In some embodiments, the formulation includes an antifoaming agent, e.g., about 0.25-0.75, 0.25-0.70, 0.25-0.65, 0.25-0.60, 0.25-0.55, 0.25-0.50, 0.25-0.45, 0.25-0.40, 0.25-0.35, 0.25-0.30, 0.30-0.75, 0.30-0.70, 0.30~0.65, 0.30~0.60, 0.30~0.55, 0.30~0.50, 0.30~0.45, 0.30~0.40, 0.30~0.35, 0.35~0.75, 0.35~0.70, 0.35~0.65, 0.35~0.60, 0.35~0.55, 0.35~0.50, 0.35~0.45, 0.35~ 0.40, 0.40~0.75, 0.40~0.70, 0.40~0.65, 0.40~0.60, 0.40~0.55, 0.40~.50, 0.40~0.45, 0.45~0.75, 0.45~0.70, 0.45~0.65, 0.45~0.60, 0.45~0.55, 0.45~0.50, 0.50~0.75, 0 0.50-0.70, 0.50-0.65, 0.50-0.60, 0.50-0.55, 0.55-0.75, 0.55-0.70, 0.55-0.65, 0.55-0.60, 0.60-0.75, 0.60-0.70, 0.60-0.65, 0.65-0.75, or 0.65-0.70 weight percent of an antifoaming agent. The antifoaming agent can be 1-octanol.In some embodiments, the formulation includes a dispersant, e.g., about 0.1-0.3, 0.1-0.25, 0.1-0.2, 0.1-0.15, 0.15-0.3, 0.15-0.25, 0.15-0.2, 0.2-0.3, 0.2-0.25, or 0.25-0.3 weight percent of a dispersant. The dispersant can be Darvan 821-A. In non-limiting embodiments, the formulation includes about 45-65 weight percent ceramic, about 20-40 weight percent deionized water, about 5-20 weight percent polymer, about 0.25-0.75 weight percent antifoam agent, and about 0.1-0.3 weight percent dispersant. For example, the formulation may include about 45-65% by weight β-TCP powder, about 20-40% by weight deionized water, about 5-20% by weight poloxamer, about 0.25-0.75% 1-octanol 407, and about 0.1-0.3% Darvan 821-A.

[0103] In other embodiments, the formulation comprises about 30% to about 50% β-TCP, for example, the formulation comprises about 30-50, 30-45, 30-40, 30-35, 35-50, 35-45, 35-40, 40-50, 40-45, 45-50, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 weight percent β-TCP. In some embodiments, the formulation includes a polymer, e.g., about 10-20, 10-18, 10-16, 10-14, 10-12, 12-20, 12-18, 12-16, 12-14, 14-20, 14-18, 14-16, or 16-18 weight percent of a polymer. The polymer can be a polyester, such as polycaprolactone (PCL). In some embodiments, the formulation includes a solvent, e.g., about 25-35, 25-33, 25-31, 25-29, 25-27, 27-33, 27-31, 27-29, 29-35, 29-33, 29-31, 31-35, or 33-35 weight percent of a solvent. The solvent can be an organic chlorine, e.g., dichloromethane (DCM) and chloroform; the solvent can be 2-butoxyethanol. In some cases, the solvent combination may include dibutyl phthalate. In some embodiments, the formulation includes an antifoaming agent, such as about 2.5-12.5, 2.5-10, 2.5-7.5, 2.5-5, 5-12.5, 5-10, 5-7.5, 7.5-12.5, 7.5-10, or 10-12.5 weight percent of an antifoaming agent. The antifoaming agent may be 2-butoxyethanol. In some embodiments, the formulation includes a plasticizer, such as about 2-6, 2-5, 2-4, 2-3, 3-6, 3-5, 3-4, 4-6, or 5-6 weight percent of a plasticizer. The plasticizer may include a phthalate, such as dibutyl phthalate (DBP), benzyl butyl phthalate (BBP), or diethylhexyl-phthalate (DEHP). In a non-limiting embodiment, the formulation comprises about 30-50% by weight ceramic, about 10-20% by weight polymer, about 25-35% by weight solvent, about 2.5-12.5% ​​by weight antifoam agent, and about 2-6% by weight plasticizer.For example, the formulation may include about 30-50% by weight β-TCP powder, about 10-20% by weight PCL, about 25-35% by weight dichloromethane, about 2.5-12.5% ​​by weight 2-butoxyethanol, and about 2-6% by weight dibutyl phthalate.

[0104] In other embodiments, the formulation comprises about 30% to about 70% β-TCP. For example, the formulation comprises about 30-70, 30-65, 30-60, 30-55, 30-50, 30-45, 30-40, 30-35, 35-70, 35-65, 35-60, 35-55, 35-50, 35-45, 35-40, 40-70, 40-65, 40-60, 40-55, 40-50, 40-45, 45-70, 45-65, 45-60, 45-55, 45-50, 50-70, 50 ~65, 50-60, 50-55, 60-70, 60-65, 65-70, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 weight percent β-TCP. In some embodiments, the formulation comprises a first polymer, e.g., about 10-30, 10-25, 10-20, 10-15, 15-30, 15-25, 15-20, 20-30, 20-25, or 25-30 weight percent of the first polymer. The first polymer can be polycaprolactone (PCL). In some embodiments, the formulation comprises a second polymer, e.g., about 10-30, 10-25, 10-20, 10-15, 15-30, 15-25, 15-20, 20-30, 20-25, or 25-30 weight percent of the second polymer. The second polymer can be polyethylene glycol (PEG). In a non-limiting embodiment, the formulation comprises about 30-70 weight percent ceramic, about 10-30 weight percent first polymer, and about 10-30 weight percent second polymer. For example, the formulation may contain about 30-70% by weight β-TCP, about 10-30% by weight PCL, and about 10-30% by weight PEG.

[0105] 3D printed structure In other aspects, 3D printed structures are provided herein. The structures can be prepared using the ink formulations and / or manufacturing methods described herein.

[0106] In some embodiments, the structure comprises a ceramic material such as calcium phosphate. In some embodiments, the structure comprises a ceramic material such as calcium phosphate. 60~100, 60~95, 60~90, 60~85, 60~80, 60~75, 60~70, 60~65, 65~100, 65~95, 65~90, 65~85, 65~80, 65~75, 65~70, 70~100, 70~95, 70~90, 70~85, 70~80, 70~75, 75~1 00, 75~95, 75~90, 75~85, 75~80, 80~100, 80~95, 80~90, 80~85, 85~100, 85~95, 85~90, 90~100, 90~95, 95~100, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 weight percent ceramic material. In some cases, the ceramic material is a calcium phosphate, such as β-tricalcium phosphate (β-TCP).

[0107] In a non-limiting example, the structure has about 90-100% ceramic material, such as β-TCP. In some cases, the structure has about 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% ceramic material, such as β-TCP. In some embodiments, the structure has about 0-10% polymer, such as Pluronic F-127. In some cases, the structure has about 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% polymer, such as Pluronic F-127. Exemplary structures include 100% by weight ceramic (e.g., β-TCP), about 100% by weight (e.g., β-TCP), about 99% by weight ceramic (e.g., β-TCP) and about 1% by weight polymer (e.g., Pluronic F-127), about 98% by weight ceramic (e.g., β-TCP) and about 2% by weight polymer (e.g., Pluronic F-127), about 97% by weight ceramic (e.g., β-TCP) and about 3% by weight polymer (e.g., Pluronic F-127), about 96% by weight ceramic (e.g., β-TCP) and about 4% by weight polymer (e.g., Pluronic F-127), about 95% by weight ceramic (e.g., β-TCP) and about 5% by weight polymer (e.g., Pluronic F-127), about 94% by weight ceramic (e.g., β-TCP) and about 6% by weight polymer (e.g., Pluronic F-127), and about 10% by weight ceramic (e.g., β-TCP) and about 10% by weight polymer (e.g., Pluronic F-127). F-127), about 93% by weight ceramic (e.g., β-TCP) and about 7% by weight polymer (e.g., Pluronic F-127), about 92% by weight ceramic (e.g., β-TCP) and about 8% by weight polymer (e.g., Pluronic F-127), about 91% by weight ceramic (e.g., β-TCP) and about 9% by weight polymer (e.g., Pluronic F-127), and about 90% by weight ceramic (e.g., β-TCP) and about 10% by weight polymer (e.g., Pluronic F-127). In an exemplary embodiment, the structure is about 100% β-TCP.

[0108] In some embodiments, the three-dimensional structure has a mass of about 1 g / cm 3 and about 3g / cm 3(e.g., between about 1, 1.1, 1.15, 1.2, 1.25, 1.3, 1.35, 1.4, 1.45, 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 1.8, 1.85, 1.9, 1.95, 2, 2.05, 2.1, 2.15, 2.2, 2.25, 2.3, 2.35, 2.4, 2.45, 2.5, 2.55, 2.6, 2.65, 2.7, 2.75, 2.8, 2.85, 2.9, 2.95, or 3 g / cm 3 In some embodiments, the three-dimensional structure has an open porosity of between about 15% and about 45% (e.g., 15, 20, 25, 30, 35, 40%, or 45%, or any value therebetween). In some embodiments, the three-dimensional structure has an open porosity of about 0.50 m 2 / g and about 1.0m 2 / g (e.g., 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 m 2 / g, or any value therebetween). In some embodiments, the three-dimensional structure has a fiber diameter of between about 325 μm and about 475 μm (e.g., 325, 350, 375, 400, 425, 450, or 475 μm, or any value therebetween).

[0109] In some embodiments, the three-dimensional structure has a mass of about 1 g / cm 3 and about 3g / cm 3 between about 15% and about 45% open porosity, and about 0.50m 2 / g and about 1.0m 2 / g, the three-dimensional structure has a fiber diameter of about 325 μm and about 475 μm.

[0110] The structures may be fabricated using 3D printing from an ink containing about 45-65% by weight ceramic, about 20-40% by weight deionized water, about 5-20% by weight polymer, about 0.25-0.75% by weight antifoaming agent, and about 0.1-0.3% by weight dispersant. For example, the structures are fabricated from an ink containing about 45-65% by weight β-TCP powder, about 20-40% by weight deionized water, about 5-20% by weight poloxamer 407, about 0.25-0.75% by weight 1-octanol, and about 0.1-0.3% by weight Darvan 821-A. Exemplary 3D printing methods using β-TCP and Pluronic F-127 inks are provided in the fabrication methods herein. In some embodiments, the structures are about 100% β-TCP.

[0111] In some embodiments, the structure has a viscosity of about 2.44 g / cm 3 It has a density of about 1.0, an open porosity of about 19.6%, and a fiber diameter of about 384 μm.

[0112] In another non-limiting example, the structure has about 50-90% ceramic material, e.g., β-TCP. In some cases, the structure has about 50, 55, 60, 65, 70, 75, 80, 85, or 90% ceramic material, e.g., β-TCP. In some embodiments, the structure has about 10-50% polymer, e.g., polycaprolactone (PCL). In some cases, the structure has about 10, 15, 20, 25, 30, 35, 40, 45, or 50% polymer, e.g., PCL. Exemplary structures include about 85-90% by weight ceramic (e.g., β-TCP) and about 10-15% by weight polymer (e.g., PCL), about 80-85% by weight ceramic (e.g., β-TCP) and about 15-20% by weight polymer (e.g., PCL), about 75-80% by weight ceramic (e.g., β-TCP) and about 20-25% by weight polymer (e.g., PCL), about 70-75 ...0-75% by weight ceramic (e.g., β-TCP) and about 10-15% by weight polymer (e.g., PCL), about 70-75% by weight ceramic (e.g., β-TCP) and about 10-15% by weight polymer (e.g., PCL), about 70-75% by weight ceramic (e.g., β-TCP) and about 10-15% by weight polymer (e.g., PCL), about 70-75% by weight ceramic (e.g., β-TCP) and about 10-15% by about 65-70% by weight of ceramic (e.g., β-TCP) and about 30-35% by weight of polymer (e.g., PCL); about 60-65% by weight of ceramic (e.g., β-TCP) and about 35-40% by weight of polymer (e.g., PCL); about 55-60% by weight of ceramic (e.g., β-TCP) and about 40-45% by weight of polymer (e.g., PCL) , about 50-55% by weight of ceramic (e.g., β-TCP) and about 45-50% by weight of polymer (e.g., PCL), about 90% by weight of ceramic (e.g., β-TCP) and about 10% by weight of polymer (e.g., PCL), about 89% by weight of ceramic (e.g., β-TCP) and about 11% by weight of polymer (e.g., PCL), about 88% by weight of ceramic (e.g., β-TCP) and about 12% by weight of polymer (e.g., PCL), about 87% by weight of ceramic (e.g., β-TCP) and about 13% by weight of polymer (e.g., PCL), about 86% by weight of ceramic (e.g., β-TCP) and about 14% by weight of polymer (e.g., PCL), about 85% by weight of ceramic (e.g., β-TCP) and about 15% by weight of polymer (e.g., PCL), about 84% by weight of ceramic (e.g., β-TCP) and about 16% by weight of polymer (e.g., PCL),about 83% by weight ceramic (e.g., β-TCP) and about 17% by weight polymer (e.g., PCL), about 82% by weight ceramic (e.g., β-TCP) and about 18% by weight polymer (e.g., PCL), about 81% by weight ceramic (e.g., β-TCP) and about 19% by weight polymer (e.g., PCL), about 80% by weight ceramic (e.g., β-TCP) and about 20% by weight polymer (e.g., PCL), about 79% by weight ceramic (e.g., β-TCP) and about 21% by weight polymer (e.g., PCL), about 78% by weight ceramic (e.g., % of a ceramic (e.g., β-TCP) and about 22% by weight of a polymer (e.g., PCL), about 77% by weight of a ceramic (e.g., β-TCP) and about 23% by weight of a polymer (e.g., PCL), about 76% by weight of a ceramic (e.g., β-TCP) and about 24% by weight of a polymer (e.g., PCL), about 75% by weight of a ceramic (e.g., β-TCP) and about 25% by weight of a polymer (e.g., PCL), about 74% by weight of a ceramic (e.g., β-TCP) and about 26% by weight of a polymer (e.g., PCL), about 73% by weight of a ceramic (e.g., β-TCP) and about 27 ...5% by weight of a ceramic (e.g., β-TCP) and about 25% by weight of a polymer (e.g., PCL), about 75% by weight of a ceramic (e.g., β-TCP) and about 25% by weight of a polymer (e.g., PCL), about 75% by weight of a ceramic (e.g., β-TCP) and about polymer (e.g., PCL), about 72% by weight ceramic (e.g., β-TCP) and about 28% by weight polymer (e.g., PCL), about 71% by weight ceramic (e.g., β-TCP) and about 29% by weight polymer (e.g., PCL), about 70% by weight ceramic (e.g., β-TCP) and about 30% by weight polymer (e.g., PCL), about 69% by weight ceramic (e.g., β-TCP) and about 31% by weight polymer (e.g., PCL), about 68% by weight ceramic (e.g., β-TCP) and about 32% by weight polymer (e.g., PCL), about 67% about 66% by weight of ceramic (e.g., β-TCP) and about 34% by weight of polymer (e.g., PCL), about 65% by weight of ceramic (e.g., β-TCP) and about 35% by weight of polymer (e.g., PCL), about 64% by weight of ceramic (e.g., β-TCP) and about 36% by weight of polymer (e.g., PCL), about 63% by weight of ceramic (e.g., β-TCP) and about 37% by weight of polymer (e.g., PCL), about 62% by weight of ceramic (e.g., β-TCP),About 38% by weight of a polymer (e.g., PCL) and about 61% by weight of a ceramic (e.g., β-TCP) and about 39% by weight of a polymer (e.g., PCL), about 60% by weight of a ceramic (e.g., β-TCP) and about 40% by weight of a polymer (e.g., PCL), about 59% by weight of a ceramic (e.g., β-TCP) and about 41% by weight of a polymer (e.g., PCL), about 58% by weight of a ceramic (e.g., β-TCP) and about 42% by weight of a polymer (e.g., PCL), about 57% by weight of a ceramic (e.g., β-TCP) and about 43% by weight of a polymer (e.g., PCL), about 56% by weight of a ceramic (e.g., β-TCP) and about 44% by weight of a polymer (e.g., PCL), CL), about 55% ceramic (e.g., β-TCP) and about 45% polymer (e.g., PCL), about 54% ceramic (e.g., β-TCP) and about 46% polymer (e.g., PCL), about 53% ceramic (e.g., β-TCP) and about 47% polymer (e.g., PCL), about 52% ceramic (e.g., β-TCP) and about 48% polymer (e.g., PCL), about 51% ceramic (e.g., β-TCP) and about 49% polymer (e.g., PCL), and about 50% ceramic (e.g., β-TCP) and about 50% polymer (e.g., PCL).

[0113] The structure may be fabricated using 3D printing from an ink containing about 30-50% by weight β-TCP powder, about 10-20% by weight polymer, about 25-35% by weight solvent, about 2.5-12.5% ​​by weight defoamer, and about 2-6% by weight plasticizer. For example, the structure may be fabricated using 3D printing from an ink containing about 30-50% by weight β-TCP powder, about 10-20% by weight PCL, about 25-35% by weight dichloromethane, about 2.5-12.5% ​​by weight 2-butoxyethanol, and about 2-6% by weight dibutyl phthalate. The structure may be fabricated using 3D printing from an ink containing about 30-70% by weight ceramic, about 10-30% by weight first polymer, and about 10-30% by weight second polymer. For example, structures can be fabricated from an ink containing about 30-70% by weight β-TCP, about 10-30% by weight PCL, and about 10-30% by weight PEG.

[0114] In some embodiments, the structure has a viscosity of about 1.32 g / cm 3 It has a density of about 100%, an open porosity of about 38%, and a fiber diameter of about 394 μm.

[0115] In some embodiments, the structure has a viscosity of about 1.49 g / cm 3 density, approximately 31% open porosity, 0.81m 2 / g and a fiber diameter of about 420 μm.

[0116] In some embodiments, the structure has a modulus of elasticity (stiffness) of about 100-150, 100-140, 100-130, 100-120, 100-110, 110-150, 110-140, 110-130, 110-120, 120-150, 120-140, 120-130, 130-150, 130-140, 140-150, 100, 115, 120, 125, 130, 135, 140, 145, or 150 MPa.

[0117] In some embodiments, the composition of the ink formulations herein is altered to optimize the specific surface area. The surface area may be optimized for combination with a therapeutic agent. For example, the structure may be optimized to have a specific surface area of ​​about 0.2 to 2 m for combination with a BMP protein (e.g., tBMP-2). 2In some embodiments, the surface area of ​​the structures herein is about 0.2-2, 0.2-1.8, 0.2-1.6, 0.2-1.4, 0.2-1.2, 0.2-1, 0.2-0.8, 0.2-0.6, 0.2-0.4, 0.4-2, 0.4-1.8, 0.4-1.6, 0.4-1.4, 0.4-1.2, 0.4-1, 0.4-0.8, 0.4-0.6, 0.6-2, 0.6-1.8, 0.6-1.6 , 0.6~1.4, 0.6~1.2, 0.6~1, 0.6~0.8, 0.8~2, 0.8~1.8, 0.8~1.6, 0.8~1.4, 0.8~1.2, 0.8~1, 1~2, 1~1.8, 1~1.6, 1~1.4, 1~1.2, 1.2~2, 1.2~1.8, 1.2~1.6, 1.2~1.4, 1.4~2, 1.4~1.8, 1.4~1.6, 1.6~2, 1.6~1.8, or 1.8~2m 2 / g. In some embodiments, the surface area is calculated by Brunauer-Emmett-Teller (BET) by gas physisorption.

[0118] Manufacturing method In another aspect, a method of manufacturing a structure using 3D printing technology is provided.

[0119] 1) β-tricalcium phosphate ink Referring to Figure 1A, an exemplary process (100) for preparing a strong calcium phosphate ceramic implantable structure (160) is described. The implantable structure (160) is formed from a calcium phosphate ceramic ink (120), which is a mixture of calcium phosphate ceramic powder, a water-soluble polymeric binder, water, a dispersant, and an antifoaming agent. The structure (135) printed with the calcium phosphate ceramic ink (120) is first dried and then heat treated to pyrolyze the water-soluble polymeric binder and densify the remaining ceramic material to about 80% or more of theoretical density by high temperature sintering.

[0120] The process (100) includes a mixing step to prepare an extrudable calcium phosphate ceramic ink (120), a 3D printing step where the prepared calcium phosphate ceramic ink (120) is dispensed by a 3D printer (130) to create a printed structure (135), a drying step where the printed structure (135) is placed in a drier set-up (140), and a final heat treatment step where the dried scaffold or compact (145) is placed in a heater (150) to remove the water soluble polymer binder and sinter the calcium phosphate ceramic powder to form the final implantable structure (160).

[0121] The calcium phosphate ceramic ink (120) is powder-filled and contains Pluronic® F-127 hydrogel material (Sigma-Aldrich, Missouri) which acts as both a gelling agent and a polymeric binder material for the ceramic compact (145) (after drying). Pluronic® F-127 hydrogel is liquid at 4° C. and transitions to a gel material at room temperature. The gel properties of Pluronic® F-127 hydrogel allow the filaments extruded by the 3D printer (130) to maintain their shape during the printing process (which takes place at room temperature). An exemplary formulation of the extrudable calcium phosphate ceramic ink (120) is described in Table 1.

[0122] [Table 1]

[0123] Referring also to FIG. 1B, an exemplary method (102) for making a calcium phosphate ceramic ink (120) is illustrated. First, a polymer solution is prepared using Pluronic® F-127 solution (step 162). Preparing the Pluronic® F-127 solution involves first preparing a stock of 24.5% Pluronic® F-127 solution by placing 37.75 g of deionized water in a container (e.g., a 75 cc polypropylene container) and cooling by partial immersion in an ice bath. The ice bath is transferred to a stir plate (110) (illustrated in FIG. 1A) and a magnetic stir bar is added to the container to vigorously mix the contents. 12.25 g of Pluronic® F-127 powder is added to 37.75 g of deionized water while constantly stirring on the stir plate (110). The mixture is stirred for about 1 hour or until the Pluronic® F-127 powder is completely dissolved.

[0124] Thereafter, 6.438 g of the cold 24.5% Pluronic® F-127 solution that has been prepared is combined (e.g., in a 30 cc stoppered syringe) with the dispersant and antifoaming agent (step 164) to make a 10 cc batch of calcium phosphate ceramic ink (120). In this exemplary method (102), 0.033 g of Darvan® 821-A (Vanderbilt Minerals, Connecticut) and 0.082 g of 1-octanol are added to the 24.5% Pluronic® F-127 solution. This combination of Pluronic® F-127 solution, Darvan® 821-A, and 1-octanol is then homogenized, for example, in a FlackTek Speedmixer at 3500 rpm for 1 minute.

[0125] The mixed solution is then combined with calcium phosphate powder, in this case β-TCP powder. This addition of powder is done stepwise, for example, splitting 10.745 g of β-TCP powder into three batches. The first 1 / 3 of the powder is added to the solution (step 166) and mixed at 2500 rpm for 1 minute to wet the powder (step 168). These steps are repeated by adding the second 1 / 3 of the powder (repeat step 166) and mixing again at 2500 rpm for 1 minute (repeat step 168), and then the last 1 / 3 of the powder is mixed again at 2500 rpm for 1 minute. If the powder remains unwetted, as determined in step (170), the sides of the container containing the solution and powder are scraped with a spatula to incorporate the dry powder into the wet solution, and the ink mixture is mixed at 3500 rpm for 1 minute (step (172)). The ink mixture is again evaluated as to whether the powder is sufficiently wetted (step 170) and the rubbing and mixing steps are repeated if necessary. Once all the powder is wetted, a final mixing / dispersion step is performed with a final mix at 3500 rpm for 5 minutes (step (174)). The prepared calcium phosphate ceramic ink (120) is ready for use in 3D printing and the 3D printed structure (165) may be further processed.

[0126] Referring back to FIG. 1A, the prepared calcium phosphate ceramic ink (120) is ready for use in a printer (130). For example, the calcium phosphate ceramic ink (120) may be used for printing with an Allevi 2 Bioprinter (Allevi, Pennsylvania) using a 10 cc syringe. In some examples, the calcium phosphate ceramic ink (120) may be printed using a 400 micron inner diameter conical metal luer lock tip using 90 psi pressure and a tip speed of 14 mm / s. In other examples, the ink (120) may be printed using a 625 micron inner diameter conical metal luer lock tip using 70 psi pressure and a tip speed of 14 mm / s. The printed structure (135) may be printed on Teflon plumber's tape applied to a smooth glass surface as a build platform, such as a glass slide or a larger glass plate.

[0127] Once the 3D printing process is complete, the printed structure (135) is placed into a drier device (140), such as a plastic box with a loosely attached lid, and the printed structure (135) is left at room temperature overnight to allow for evaporation of the water from the 3D printed calcium phosphate ceramic ink (120) and form the printed structure (135). Evaporation results in a rigid ceramic body (145) in which the β-TCP powder is bound together by the dried Pluronic® F-127 polymer.

[0128] The compact (145) is then heat treated in a heater (150) using a combined binder burn-out / sintering heat treatment that first removes the Pluronic® F-127 polymer binder and then sinters the remaining ceramic β-TCP powder. For example, the compact (145) is placed in the heater (150), which is a 1200° C. maximum temperature muffle furnace located inside a fume hood.

[0129] The burn-out portion of the first binder heat treatment includes a temperature ramp from room temperature to 600°C at a heating rate of 1°C / min, followed by a hold at 600°C for 1 hour. The sintering portion of the heat treatment includes a ramp from 600°C to 1140°C at a rate of 5°C / min, followed by a hold at 1140°C for 4 hours. The burn-out and sintered body is then cooled, with a cooling ramp from 1140°C to room temperature at a rate of 5°C / min. The result is an embedded structure (160) with a density of approximately 2.44 g / cc, or 79.4% of the theoretical density of β-TCP (measured using the Archimedes method).

[0130] Although the calcium phosphate ceramic ink (120) is described as being formulated with β-TCP ceramic powder, in some embodiments, the powder filler may be bone regenerating materials such as hydroxyapatite or bioglass (e.g., Combeite 45S5 Bioactive Glass), other ceramics, or demineralized bone matrix. Drying and thermal processing steps (e.g., drying conditions, binder burnout heat schedule, sintering heat schedule, and maximum temperature) are appropriately modified based on each material.

[0131] 2) β-tricalcium phosphate / polycaprolactone composite ink Referring to FIG. 2A, in another embodiment, the calcium phosphate polymer ink (220) results in a printed structure that is flexible, porous, and easy for the user (e.g., surgeon) to handle. The calcium phosphate polymer ink (220) includes a mixture of calcium phosphate ceramic powder, a polymer binder (in this example, polycaprolactone or PCL), and three solvents with different vapor pressures (at room temperature). The exemplary process (200) illustrated in FIG. 2A includes a mixing step to create an extrudable calcium phosphate polymer ink (220). The prepared phosphate polymer ink (220) is then printed with a 3D printer (230) to form a printed structure (235). The printed structure (235) is dried to evaporate the highly volatile solvent, forming a dry mass (245) as the dissolved polymer material condenses, binding the ceramic particles of the printed structure (235) together and providing flexibility. The remaining low volatility solvent is removed from the dried body (245) by successive immersions in an ethanol / water mixture (250) followed by water (255). Fabrication of the final calcium phosphate polymer composite implantable structure (260) does not require thermal processing after 3D printing. An exemplary formulation of the extrudable calcium phosphate polymer ink (220) is listed in Table 2.

[0132] [Table 2]

[0133] The three-solvent blend with various vapor pressures allows for the initial curing of the printed filament of calcium phosphate polymer ink (220) extruded from the printer (230) as the highly volatile dichloromethane evaporates first. The two less volatile solvents (2-butoxyethanol and dibutyl phthalate) retard the precipitation of the dissolved PCL binder, which allows it to coat the β-TCP powder and neck between adjacent particles while also creating an interconnected porous network. Additionally, the less volatile solvents remain within the printed structure (235) for some time, which facilitates the fusion of the printed filament to adjacent 3D printed filaments (either beside or on top of the pre-extruded filament).

[0134] 2B, an exemplary method (102) for preparing calcium phosphate polymer ink (220) is illustrated. To prepare a 10.2 cc batch of calcium phosphate polymer ink (220), first a polymer solution is prepared (step 264). This is a PCL solution formed by combining PCL and a solvent in a container (210). First, 5.09 g of dichloromethane is mixed with 1.27 g of 2-butoxyethanol, and then 0.64 g of dibutyl phthalate is added to 2 g of PCL powder. The solution is mixed, for example, in a FlackTek Speedmixer at 3500 rpm for 5 minutes to dissolve the PCL in the solvent blend.

[0135] Then, calcium phosphate powder (β-TCP spray-dried powder) is added (step 266). This addition is performed in stages, where ∼5 g of β-TCP spray-dried powder is added to the PCL solution, which is then mixed at 2500 rpm for 2 minutes to wet the powder (step 268). ∼2 g of β-TCP spray-dried powder is added (return to step 266) to wet the powder, and mixed at 2500 rpm for 2 minutes (return to step 268). Finally, ∼1 g of β-TCP spray-dried powder is added to the mixture, which is mixed again at 2500 rpm for 2 minutes to wet the powder.

[0136] Once all of the β-TCP spray dried powder has been added, it is determined whether all of the powder is wet (step (270)). If not, the sides of the container are scraped down with a spatula and the dry powder is incorporated into the wet solution and mixed at 3500 rpm for 1 minute (step (272)). The scraping and mixing steps are repeated as necessary. Once all of the powder is wet, a final mixing / dispersion step is performed with a final mix at 3500 rpm for 5 minutes (step (274)). The prepared calcium phosphate polymer ink (220) is ready for use in 3D printing and further processing of the 3D printed structure (265) (step (276)).

[0137] With reference to FIG. 2A, the prepared calcium phosphate polymer ink (220) is then ready for use in a 3D printer (230). For example, the calcium phosphate polymer ink (220) can be used for printing using an Allevi 2 Bioprinter extruding the calcium phosphate polymer ink (220) from a 10 cc syringe. The calcium phosphate polymer ink (220) can be printed using a 400 micron inner diameter conical metal luer lock tip using a pressure of 20-25 psi and a tip speed of 15 mm / s.

[0138] The printed structure (235) may be printed onto a smooth glass surface as a build platform, such as a glass slide or a larger glass plate, or onto painter's tape applied onto a 2 mm thick silicone gasket material. The 3D printed structure (235) is allowed to dry in place on the build platform of the printer (230) for approximately 15-30 minutes. The printed structure (235) will naturally separate from the build platform of the printer (230) at this point and can be handled.

[0139] To remove residual solvent within the printed structures (235), they are washed in an ethanol / water mixture (250) (e.g., 70% ethanol for 30 min) and then immersed in water (255) (e.g., followed by two washes in deionized water for 30 min each).

[0140] The calcium phosphate polymer ink (220) may be formulated with other bone regenerating powder materials such as hydroxyapatite, bioglass, other ceramics, or demineralized bone matrix.

[0141] Figure 2C shows a scanning electron microscope (SEM) micrograph of a printed structure (235) fabricated with the prepared calcium phosphate polymer ink 220. The printed structure (235) in this example is a lattice structure and is shown at three magnifications (20X, 100X, and 500X).

[0142] 3) β-tricalcium phosphate / polycaprolactone composite ink Referring to FIG. 3A, a composite ink (320) is used to 3D print (by melt extrusion) a porous, flexible, embeddable structure (360) that includes a blend of β-TCP powder, a water-insoluble polymer (PCL), and a water-soluble polymer (polytheylene glycol). After printing with a 3D printer (330), the water-soluble polymer components are leached out of the material, resulting in a porous structure that exposes the β-TCP powder that was previously trapped inside the 3D printed filament. After leaching out the water-soluble components, the flexibility of the 3D printed structure is enhanced. A sample formulation of the extrudable composite ink (220) is listed in Table 3.

[0143] [Table 3]

[0144] Referring also to FIG. 3B, the various powders are combined (step (364)) to make a 3.2 cc batch of mixed ink (320). 2.062 g of β-TCP powder, 2.062 g of PCL powder, and 0.884 g of polyethylene glycol flakes are added to a container (310) (e.g., a glass bottle). The container (310) is placed in a mixer and the powders are mixed, e.g., in a FlackTek Speedmixer, at 300 rpm for 2 minutes to homogenize the powder blend. Higher rpm mixing is then performed (step (366)) for an additional 5 minutes at 3500 rpm to melt the powders. During this mixing, internal friction melts the PCL and polyethylene glycol, turning the powders into a sticky molten liquid. This liquid phase mixing promotes the intimate dispersion of the β-TCP powder into the molten polymer blend. Thus, while the composite ink (320) is still molten and tacky, it can be roughly shaped with a spatula or cut into small pieces (322) that fit within the printer syringe (330) (step (368)). For example, the ink can be cut into pieces of .about.1 cm. 3 The solid PCL / β-TCP mass may be cut into pieces the size of 100 μm. A solid PCL / β-TCP mass of this size can fit into a syringe for melt extrusion printing, for example, using an Allevi 2 Bioprinter extruding the composite ink (320) from a 10 cc stainless steel syringe. This can be a syringe with a 400 micron inner diameter conical metal luer lock tip using 90 psi pressure and a tip speed of 5 mm / s to 10 mm / s.

[0145] The composite ink (320) is then generally ready for 3D printing and further processing of the printed structure (335) (step (376)). Prior to printing with the printer (330), the extruder chamber (e.g., a stainless steel syringe) is heated to ensure melting of the composite ink (320). The ink is heated to 100°C-110°C and allowed to dwell for an hour. The molten ink can then be applied to a smooth glass surface, such as a glass slide or a larger glass porcelain, on painter's tape to create the printed structure (335).

[0146] The printed structure (335) is then immersed in distilled water (350) overnight (or longer depending on the size of the printed object) to dissolve the polyethylene glycol from the print and create a porous and flexible β-TCP / PCL composite embedded structure (360).

[0147] The composite ink (320) may be formulated with other regenerative powder materials such as hydroxyapatite or bioglass, or other ceramics, or demineralized bone matrix. It may also be formulated with other biocompatible polymers such as poly(lactic-co-glycolic acid), poly(lactic acid), or poly(L-lactide-co-caprolactone).

[0148] Figure 3C shows an SEM micrograph of a printed structure 335 fabricated with the prepared composite ink 320. The printed structure 335 in this example is a lattice structure and is shown at three magnifications (20X, 100X, and 1000X).

[0149] Any of the 3D printed implantable structures (160), (260), (360) described herein are then coated with an anchorable protein (e.g., tBMP2) as part of the processing of the 3D implantable structure (steps (176), (276), (376)). After completion of the implantable structure, the implantable structure may be washed with an acidic sodium acetate buffer using any of the methods described above. This may be one, two, or more washes. The wash may be followed by a 2 hour incubation of the 3D implantable structure in a sodium acetate buffer containing tBMP2 protein at a concentration of 1 mg / mL. The anchorable tBMP2 binds to the β-TCP surface of the monolayer implantable structure.

[0150] In some embodiments, a bone putty (rather than a 3D printed component) is used to deliver tetherable tBMP2 to the bone regeneration site. The putty material is roughly molded by hand to the shape and size of the bone void and inserted into the cavity where bone regeneration is desired. Sodium carboxymethylcellulose (CMC) hydrogel can be mixed with β-TCP granules coated with tBMP2 to create a putty that fills the bone void. A putty of 50 wt% β-TCP (coated with tBMP2) and 50 wt% sodium CMC hydrogel can be formulated using dual asymmetric centrifugal mixing. To make a 6 wt% sodium CMC hydrogel, 10.5 g of deionized water is placed in a polypropylene container and 0.9 g of sodium CMC powder is added to the water. The material is mixed in a FlackTek Speedmixer at 3500 rpm for 10-11 minutes to completely dissolve the sodium carboxymethylcellulose powder, and the resulting material is a very cohesive gel. Then, 3.6 g of additional deionized water is added to dilute the thick gel and mixed for 2 min at 3500 rpm. Then, 15 grams of β-TCP granules (250 μm to 1000 μm, pre-coated with tBMP2) are added in incremental amounts (e.g., 5 g, 5 g, 5 g), followed by mixing for 1 min at 2500 rpm after each granule addition. A final mixing step for 2 min at 3500 rpm is performed to completely homogenize the putty (asymmetric centrifugal mixing). Before mixing the β-TCP granules into the hydrogel, the β-TCP particles are coated with tBMP2.

[0151] In further embodiments, the ink formulations described herein can include a photosensitive resin mixed with ceramic powder for digital light processing (DLP), an additive manufacturing technique that is faster than robocasting or melt extrusion. The components in a photosensitive ceramic-filled resin for DLP 3D printing of bone implants typically include ceramic powder (e.g., β-TCP, hydroxyapatite, bioglass, typically with particle size ≦10 μm), one or more crosslinked acrylates or methacrylates (e.g., polyethylene glycol diacrylate, polycaprolactone methacrylate), a plasticizer (e.g., water) to reduce resin viscosity, a dispersant (e.g., Darvan®, 821-A) to promote breakup of powder aggregates, a photoinitiator to initiate a photocrosslinking reaction (e.g., lithium phenyl-2,4,6-trimethylbenzoylphosphinate), and a photoabsorber (e.g., tartrazine) to preserve high xy resolution. Once the resin formulation is prepared by asymmetric centrifugal mixing of the components, the ink is exposed layer by layer to a DLP image, which selectively solidifies the illuminated pixels when the resin is exposed to light. Once the implantable structure is built up layer by layer, it is either heat treated to sinter the included polymer and densify the ceramic (e.g., resins containing polyethylene glycol diacrylate) or left as is, resulting in a flexible ceramic / polymer composite implant (e.g., resins containing polycaprolactone methacrylate).

[0152] device In other aspects, devices and kits are provided that include the 3D printed structures described herein and therapeutic agents.In some embodiments, the devices include therapeutic agents that are connected to, dispersed within, or otherwise combined with the 3D printed structures.As used herein, therapeutic agents include multiple therapeutic agents, such as 2, 3, 4, or 5 therapeutic agents.

[0153] Therapeutic Agents In some embodiments, the therapeutic agent comprises a mammalian growth factor or a functional portion thereof. The mammalian growth factor may be an osteoinductive molecule capable of initiating or enhancing bone repair processes. The functional portion of the mammalian growth factor is a region having a therapeutic effect. For example, the functional portion of the mammalian growth factor is osteoinductive. As another example, the functional portion of the mammalian growth factor can initiate and / or enhance bone repair. The functional portion of the mammalian growth factor may have osteogenic activity.

[0154] Non-limiting examples of mammalian growth factors are described herein. In some examples, the mammalian growth factor is selected from the group consisting of epidermal growth factor (EGF), platelet derived growth factor (PDGF), insulin-like growth factor (IGF-1), fibroblast growth factor (FGF), fibroblast growth factor 2 (FGF2), fibroblast growth factor 18 (FGF18), transforming growth factor alpha (TGF-α), transforming growth factor beta (TGF-β), transforming growth factor beta 1 (TGF-β1), transforming growth factor beta 3 (TGF-β3), osteogenic protein (OP-1), bone morphogenetic protein 2 (OP-2), bone morphogenetic protein 3 (OP-3), bone morphogenetic protein (BMP ...Bone morphogenetic protein 2 (BMP-2), bone morphogenetic protein 3 (BMP-3), bone morphogenetic protein 4 (BMP-4), bone morphogenetic protein 5 (BMP-5), bone morphogenetic protein 6 (BMP-6), bone morphogenetic protein 7 (BMP-7), bone morphogenetic protein 9 (BMP-9), bone morphogenetic protein 10 (BMP-10), bone morphogenetic protein 11 (BMP-11), bone morphogenetic protein 12 (BMP-12), bone morphogenetic protein 13 (BMP-13), bone morphogenetic protein 15 (BMP-15), dentin phosphoprotein (DPP), plant associated growth factor receptor (DRR) receptor (DRP) receptor phosphoprotein (PGP), Growth differentiation factor (Vgr), growth differentiation factor 1 (GDF-1), growth differentiation factor 3 (GDF-3), growth differentiation factor 5 (GDF-5), growth differentiation factor 6 (GDF-6), growth differentiation factor 7 (GDF-7), growth differentiation factor 8 (GDF8), growth differentiation factor 11 (GDF11), growth differentiation factor 15 (GDF15), vascular endothelial growth factor (VEGF), hyaluronan binding protein (HABP), and collagen binding protein (CBP), fibroblast growth factor 18 (FGF-18), keratinocyte growth factor (KGF), tumor necrosis factor alpha (TNFα), tumor Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), wnt family member 1 (WNT1), wnt family member 2 (WNT2), wnt family member 2B (WNT2B), wnt family member 3 (WNT3), wnt family member 3A (WNT3A), wnt family member 4 (WNT4), wnt family member 5A (WNT5A), wnt family member 5B (WNT5B), wnt family member 6 (WNT6), wnt family member 7A (W WNT7A), wnt family member 7B (WNT7B), wnt family member 8A (WNT8A), wnt family member 8B (WNT8B), wnt family member 9A (WNT9A), wnt family member 9B (WNT9B), wnt family member 10A (WNT10A), wnt family member 10B (WNT10B), wnt family member 11 (WNT11), or wnt family member 16 (WNT16), or a mature peptide or functional portion thereof.

[0155] In some embodiments, the mammalian growth factor is a human growth factor. Non-limiting examples of human growth factors and mature peptides and / or functional portions thereof are provided in Table 4. In some embodiments, the mammalian growth factor comprises a sequence that is at least 70% identical (e.g., at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 99% identical) to any of the sequences in Table 4 or any secreted human growth factor and has osteogenic activity. In some embodiments, amino acids in mammalian growth factors that are conserved among various species may be important for osteogenic activity and may not be mutated, while amino acids in mammalian growth factors that are not conserved among various species may be important for osteogenic activity and may be mutated.

[0156] In some embodiments, the mammalian growth factor comprises BMP-2. In some embodiments, the mammalian growth factor is a mature peptide of BMP-2 (e.g., does not include a signal sequence). In some embodiments, the mammalian growth factor comprises a functional portion of BMP-2. In some embodiments, the functional portion of BMP-2 comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR (SEQ ID NO: 454). In some embodiments, the mammalian growth factor comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 454. In some embodiments, the mammalian growth factor comprises a sequence at least about 90% identical to SEQ ID NO: 454. In some embodiments, the mammalian growth factor comprises SEQ ID NO:454.

[0157] In some embodiments, the mammalian growth factor is a non-human mammalian growth factor. The non-human mammalian growth factor may be homologous to a human growth factor, such as one or more of the human growth factors in Table 4. In some embodiments, the non-human mammalian growth factor is homologous to a human growth factor if the non-human mammalian growth factor is at least about 80% identical to the human mammalian growth factor as determined using the NCBI Blast alignment algorithm as of the date of this application. In some examples, the coverage is at least about 90%. In some embodiments, the non-human mammalian growth factor is homologous to a human growth factor if the non-human mammalian growth factor is at least about 80% positive compared to the human mammalian growth factor as determined using the NCBI Blast alignment algorithm as of the date of this application. In some examples, the coverage is at least about 90%. In some embodiments, a non-human mammalian growth factor is homologous to a human growth factor if, as of the filing date of this application, the non-human mammalian growth factor aligns to the human growth factor using NCBI Blast and has an E-value of about 1E-40, at least about 1E-50, 1E-60, 1E-70, or less than 1E-10, with at least about 90% query coverage.

[0158] [Table 4-1]

[0159] [Table 4-2]

[0160] [Table 4-3]

[0161] [Table 4-4]

[0162] [Table 4-5]

[0163] [Table 4-6]

[0164] targeting part In some embodiments, the device or kit includes a targeting moiety that tethers the therapeutic agent to the structure. In some embodiments, the targeting moiety is connected to the therapeutic agent and the moiety is non-covalently bound to the structure. As a non-limiting example, the targeting moiety is covalently bound to the therapeutic agent by a peptide bond. For example, the targeting moiety includes a targeting peptide, and the targeting peptide is linked to the therapeutic agent by a peptide bond.

[0165] In some embodiments, the targeting moiety has an affinity for the structure, or a component of the structure, e.g., a ceramic material of the structure, such as calcium phosphate. In some embodiments, the dissociation constant (KD) for binding between the targeting moiety and the structure or a component thereof is (i) at least about 1 fM, at least about 10 fM, at least about 100 fM, or at least about 1 pM, and (ii) less than about 100 μM, less than about 90 μM, less than about 80 μM, less than about 70 μM, less than about 60 μM, less than about 50 μM, less than about 40 μM, less than about 30 μM, less than about 20 μM, less than about 10 μM, less than about 5 μM, less than about 1 μM, or less than about 100 pM. For example, the targeting moiety can bind to β-tricalcium phosphate with an affinity of about 100 fM to about 100 μM, about 1 pM to about 100 μM, about 10 pM to about 100 μM, about 100 pM to about 100 μM, or about 1 μM to about 100 μM.

[0166] In some embodiments, the targeting moiety comprises one or more targeting peptides, each of which binds to the structure. In some embodiments, the targeting peptide binds to the ceramic material of the structure. For example, the targeting peptide binds to calcium phosphate (e.g., tricalcium phosphate, beta-tricalcium phosphate, alpha-tricalcium phosphate), hydroxyapatite, fluorapatite, bone (e.g., demineralized bone), glass (bioglass), such as silicate, vanadate, and related ceramic minerals, or chelated divalent metal ions, or combinations thereof. In some embodiments, the targeting peptide comprises two or more targeting peptides. In some embodiments, the two or more targeting peptides are about 50, 45, 40, 35, 30, 25, 20, 15, or 10 or less targeting peptides. In some embodiments, the two or more targeting peptides are about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, or 30 targeting peptides. In some embodiments, the two or more targeting peptides are about 2 to about 10 targeting peptides. In some embodiments, the two or more targeting peptides are about 5 targeting peptides.

[0167] In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:1. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:2. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:3. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:4. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:5. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:6. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:7. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:8. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:9. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:10. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 11. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 12. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 13.In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 14. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 15. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 16. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 17. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 18. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 19. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 20. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 21. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 22. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 23. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 24. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 25. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 26.In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 27. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 28. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 29. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 30. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 31. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:32. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:33. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:34. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:35. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:36. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 37. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 38. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 39.In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 40. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 41. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 42. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 43. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 44. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 45. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 46. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 47. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 48. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 49. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 50. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 51. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 52.In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:53. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:54. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:55. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:56. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO:57. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 58. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 59. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 60. In some embodiments, the targeting peptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 61.

[0168] [Table 5-1]

[0169] [Table 5-2]

[0170] In some embodiments, the targeting peptide comprises one or more sequences in Table 5. In some embodiments, the targeting peptide comprises a sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to a sequence in Table 5.

[0171] [Table 6-1]

[0172] [Table 6-2]

[0173] [Table 6-3]

[0174] [Table 6-4]

[0175] [Table 6-5]

[0176] In some embodiments, the targeting peptide comprises one or more sequences in Table 6. In some embodiments, the targeting peptide comprises a sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to a sequence in Table 6.

[0177] Additional targeting peptides useful in the present disclosure include any one of SEQ ID NO:1-558 of U.S. Patent No. 7,572,766, the contents of which are incorporated by reference in their entirety. In some embodiments, the targeting peptide comprises a sequence that is at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NO:1-558 of U.S. Patent No. 7,572,766.

[0178] In some embodiments, the device or kit comprises a chimeric polypeptide comprising a targeting peptide and a targeting moiety. In some cases, the chimeric polypeptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 433 (ASGAGGSEGGGSEGGTSGATGAGTSTSGGGASTGGGTGQAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR). In some cases, the chimeric polypeptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 434 (MPIGSLLADTTHHRPWTVIGESTHHRPWSIIGESSHHKPFTGLGDTTHHRPWGILAESTHHKPWTASGAGGSEGGGSEGGTSGATGAGTSTSGGGASTGGGTGQAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR). In some cases, the chimeric polypeptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 435 (LLADTTHHRPWTVIGESTHHRPWSIIGESSHHKPFTGLGDTTHHRPWGILAESTHHKPWTASGAGGSEGGGSEGGTSGATGAGTSTSGGGASTGGGTGQAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR).In some cases, the chimeric polypeptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 436 (VIGESTHHRPWSIIGESSHHKPFTGLGDTTHHRPWGILAESTHHKPWTASGAGGSEGGGSEGGTSGATGAGTSTSGGGASTGGGTGQAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR). In some cases, the chimeric polypeptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 437 (IIGESSHHKPFTGLGDTTHHRPWGILAESTHHKPWTASGAGGSEGGGSEGGTSGATGAGTSTSGGGASTGGGTGQAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR). In some cases, the chimeric polypeptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 438 (GLGDTTHHRPWGILAESTHHKPWTASGAGGSEGGGSEGGTSGATGAGTSTSGGGASTGGGTGQAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR).In some cases, the chimeric polypeptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 439 (ILAESTHHKPWTASGAGGSEGGGSEGGTSGATGAGTSTSGGGASTGGGTGQAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR). In some cases, the chimeric polypeptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 440 ((X)QAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR), where X comprises a targeting peptide and optionally a linker. For example, the targeting peptide comprises one or more of SEQ ID NOs: 1-41. In some cases, the chimeric polypeptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 441 ((X)ASGAGGSEGGGSEGGTSGATGAGTSTSGGGASTGGGTGQAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR), where X comprises a targeting peptide and optionally a linker. For example, the targeting peptide comprises one or more of SEQ ID NOs: 1-41.

[0179] In some embodiments, the therapeutic agent is not connected to the structure using a targeting moiety. For example, the therapeutic agent may interact with the structure by non-covalent bonds. The therapeutic agent may be connected to the structure by hydrogen bonds, ionic bonds, hydrophobic interactions, or van der Waals forces. The therapeutic agent may also be connected to the structure using covalent bonds. Examples of methods for connecting using covalent bonds include chemical linkers and spacers used to modify active groups in proteins, such as amines, thiols, and carbohydrates.

[0180] Device fabrication Further provided herein are methods of manufacturing a device comprising a structure and a therapeutic agent. Some methods include (a) providing a first solution of a therapeutic agent (e.g., a chimeric polypeptide comprising a therapeutic agent and a targeting moiety), (b) providing a 3D structure, and (c) combining (a) and (b). In some embodiments, the therapeutic agent is present in the first solution at a concentration of about 0.25-1.5, 0.25-1.25, 0.25-1, 0.25-0.75, 0.25-0.5, 0.5-1.5, 0.5-1.25, 0.5-1, 0.5-0.75, 0.75-1.5, 0.75-1.25, 0.75-1, 1-1.5, 1-1.25, 1.25-1.5, 0.25, 0.5, 1, 1.25, or 1.5 mg / mL. In some methods, step (c) is performed at about 10-240, 10-180, 10-120, 20-240, 20-180, 20-120, 30-240, 30-180, 30-120, 40-240, 40-180, 40-120, 50-240, 50-180, 50-120, 60-240, 60-180, 60-120, 70-240, 70-180, 70-120, 80-240, 80-180, 80-120 , 90-240, 90-180, 90-120, 100-240, 100-180, 100-120, 110-240, 110-180, 110-120, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, or 240 minutes. In some methods, step (c) includes incubating the structure with the first solution by movement such as circulation and / or agitation (e.g., using a plate shaker). In some cases, the first solution includes a buffer. For example, the buffer includes sodium acetate and acetic acid. In some cases, the first solution has a pH of about 4 to about 5, or about 4, 4.1, 4.15, 4.2, 4.25, 4.3, 4.35, 4.4, 4.45, 4.5, 4.45, 4.6, 4.65, 4.7, 4.75, 4.8, 4.85, 4.9, 4.95, or 5. In some cases, the first solution comprises a salt.For example, the first solution may be 50-150, 50-140, 50-130, 50-120, 50-110, 50-100, 50-90, 50-80, 50-70, 50-60, 60-150, 60-140, 60-130, 60-120, 60-110, 60-100, 60-90, 60-80, 60-70, 70-150, 70-140, 70-130, 70-120, 70-110, 70-100, 70-90, 70-80, 80-150, 80-140, 80- The first solution may include sodium chloride such as 130, 80-120, 80-110, 80-100, 80-90, 90-150, 90-140, 90-130, 90-120, 90-110, 90-100, 100-150, 100-140, 100-130, 100-120, 100-110, 110-150, 110-140, 110-130, 110-120, 120-150, 120-140, 120-130, 130-150, 130-140, or 140-150. In some embodiments, the first solution includes 10 mM sodium acetate, 7 mM acetic acid, 100 mM NaCl, pH=4.75. In some embodiments, the method further comprises (d) washing the 3D structure of step (c) with a second solution, such as phosphate buffered saline (PBS). In some embodiments, the method further comprises drying the 3D structure of step (c) or step (d).

[0181] In some embodiments, the mass of therapeutic agent (e.g., therapeutic agent alone or therapeutic agent attached to a targeting moiety) per cubic centimeter of structure in the device is between about 0.05-50 (mg / cc) (e.g., about 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 mg / cc), or any number therebetween. For example, the therapeutic agent is about 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2 mg per cubic centimeter of device. One method for measuring the amount of therapeutic peptide bound to the structure includes (1) measuring the mass of the therapeutic peptide input in a first solution, (2) measuring the mass of the therapeutic agent remaining in the first solution after combination with the structure and removal from the structure, (3) if a washing step is included, measuring the mass of the therapeutic agent in a second solution, and (4) summing (2) and (3) and subtracting the sum of (4) from (1).

[0182] Treatment In other embodiments, methods are provided for treating a subject with the 3D printed structure herein.In some methods, the subject is treated with a device comprising a therapeutic peptide and a structure.In some examples, the subject has a bone fracture or bone defect.In some examples, the subject needs vertebral fusion of the spine.In some examples, the subject has a cartilage tear or cartilage defect.In some examples, the subject has cartilage loss.

[0183] In some embodiments, the subject suffers from a defect of bone, cartilage, soft tissue, tendon, fascia, ligament, organ, bone-tendon tissue, skin, osteochondral, or a combination of one or more of the aforementioned defects. In some embodiments, the defect is a lack of bone, cartilage, soft tissue, tendon, fascia, ligament, organ, bone-tendon tissue, skin, or osteochondral, or a combination of one or more of the aforementioned defects. In some embodiments, the defect in the subject results from trauma. In some embodiments, the defect in the subject results from a congenital disease. In some embodiments, the defect in the subject results from an acquired disease. In some embodiments, the defect refers to the absence, loss, and / or damage of a body tissue and / or organ. In some embodiments, "bone defect" refers to the absence or loss (e.g., partial loss) of bone at a subject's anatomical location that would be present in a control healthy subject. The bone defect may be the result of an infection (e.g., osteomyelitis), a tumor, trauma, or an adverse event of a procedure. The bone defect may further affect and cause damage to the muscles, soft tissues, tendons, or joints surrounding the bone defect. In some embodiments, bone defect comprises damage to soft tissue. In some embodiments, "cartilage defect" refers to the absence or loss (e.g., partial loss) of cartilage at a target anatomical location that would be present in a control healthy subject. Cartilage defect may be the result of disease, osteochondritis, osteonecrosis, or trauma. For example, cartilage defect may affect the knee joint.

[0184] Non-limiting examples of diseases suitable for treatment with the structures or devices described herein include osteoarthritis, disc degeneration, congenital defects, spinal stenosis, spondylolisthesis, spondylosis, fractures, scoliosis, kyphosis, spinal fusion (PLF and interbody fusion), bone trauma repair, dental repair, craniomaxillofacial repair, ankle fusion, vertebroplasty, balloon osteoplasty, navicular fracture repair, tendon-bone repair, osteoporosis, avascular necrosis, congenital skeletal deformity, rib reconstruction, subchondral bone repair, cartilage repair (e.g., at low doses), or trauma, or combinations thereof. BMP2 is also involved in the development of hair follicles, and thus the method may include treatment of hair follicles. The trauma is to bone, cartilage, soft tissue, tendon, fascia, ligament, organ, bone-tendon tissue, or skin tissue, or to osteochondral tissue. In some embodiments, the method is for treating osteochondral injury.

[0185] The treatment method may include spinal fusion. In some embodiments, spinal fusion is a surgical procedure to join two or more vertebrae. In some embodiments, spinal fusion includes PLF. In some embodiments, spinal fusion includes interbody fusion.

[0186] Provided herein are methods of promoting bone or cartilage formation in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the structures or devices described herein. Some embodiments of these methods may further comprise first selecting a subject in need of bone or cartilage formation. In some embodiments, the structure or device is administered to the subject proximate to a desired site of bone or cartilage formation in the subject.

[0187] Provided herein are methods of replacing and / or repairing bone or cartilage in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the structures or devices described herein. Some embodiments of these methods may further comprise first selecting a subject in need of bone replacement, bone repair, cartilage replacement, or cartilage repair. In some embodiments, the structure or device is administered to the subject proximate to the desired site of bone or cartilage replacement or repair in the subject.

[0188] Also provided herein are methods of treating a fracture or bone loss in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a structure or device described herein. Some embodiments of these methods may further comprise first selecting a subject suffering from a fracture or bone loss. In some embodiments, the structure or device is administered to the subject proximal to a fracture or bone loss site in the subject.

[0189] Also provided herein are methods of repairing soft tissue in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the structures or devices described herein. Some embodiments of these methods may further comprise first selecting a subject suffering from a fracture or bone loss. In some embodiments, the composition is administered to the subject proximal to a site of fracture or bone loss in the subject.

[0190] Also provided herein are methods for locally delivering a therapeutic agent to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the structures or devices described herein. Some embodiments of these methods may further comprise first selecting a subject suffering from a fracture or bone loss. In some embodiments, the structure or device is administered to the subject proximal to a site of fracture or bone loss in the subject.

[0191] Methods for determining the effectiveness of treating a fracture or bone loss in a subject are known in the art and include, for example, imaging techniques (eg, magnetic resonance imaging, x-ray, or computed tomography).

[0192] Methods for detecting bone or cartilage formation, or bone or cartilage replacement or repair in a subject are also known in the art and include, for example, imaging techniques (e.g., magnetic resonance imaging, X-ray, or computed tomography).

[0193] Animal models suitable for treating fracture or bone loss, forming bone or cartilage, or replacing or repairing bone or cartilage are known in the art.Non-limiting examples of such animal models are described, for example, in Drosse et al., Tissue Engineering Part C 14(1):79-88,2008; Histing et al., Bone 49:591-599,2011; and Poser et al., Hindawi Publishing Corporation, BioMed Research International; Article ID 348635,2014.

[0194] As used herein, a method of treatment includes administering a structure or device herein to a subject.

[0195] In some embodiments, administering comprises implanting a polypeptide or composition herein. In some embodiments, a polypeptide and / or composition herein comprising BMP-2 is administered to a subject. In some embodiments, the BMP2 comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 32. In some embodiments, the BMP-2 is administered to induce bone formation in a subject. In some embodiments, the BMP-2 is administered to induce cartilage formation. In some embodiments, the BMP-2 is administered in a spinal fusion procedure.

[0196] Further embodiments Further embodiments include: (1) an ink comprising tricalcium phosphate ceramic (β-TCP) or hydroxyapatite (HA) particles, a biocompatible water-soluble polymeric binder, a dispersant, and an antifoaming agent; (2) an ink according to embodiment 1, in which the biocompatible water-soluble polymer is Pluronic® F-127 polymer, the antifoaming agent is 1-octanol, and the dispersant is Darvan® 821-A; (3) an ink comprising tricalcium phosphate ceramic (β-TCP) or HA particles, a biocompatible water-insoluble polymer, and three or more solvents, each of which has a vapor pressure different from the vapor pressure of the other solvents; and (4) an ink according to embodiment 3, in which the biocompatible water-insoluble polymer is polycaprolactone (PCL), and the three or more solvents include dichloromethane, 2-butoxyethanol, and dibutyl phthalate. (5) An ink comprising tricalcium phosphate ceramic (β-TCP) or HA particles, a biocompatible water-soluble polymer, and a biocompatible water-insoluble polymer. (6) The ink of embodiment 5, wherein the biocompatible water-insoluble polymer is polycaprolactone (PCL) or poly(lactic-co-glycolic acid (PLGA) and the biocompatible water-soluble polymer is polyethylene glycol. (7) A three-dimensional implantable object comprising the ink of any of the previous embodiments. (8) The object of embodiment 7, wherein the object is a porous scaffold comprising a plurality of layers, each layer comprising an ink. (9) A method of treating a subject having a tissue defect, the method comprising surgically implanting the three-dimensional object of embodiment 7 into the tissue defect of the subject, thereby treating the subject. (10) A method of making an ink for three-dimensional printing, the method comprising the steps of preparing a liquid solution, combining the liquid solution with a portion of calcium phosphate ceramic (β-TCP) or HA particles, and mixing the liquid solution with the β-TCP particles by centrifugal mixing. (11) The method of embodiment 10, comprising combining the polymer solution with a dispersant and an antifoaming agent. (12) The method of embodiment 10, comprising combining at least an additional portion of the β-TCP or HA particles and repeating the mixing step at least once.(13) The method of embodiment 10, comprising ensuring that all β-TCP or hydroxyapatite particles are wetted by the liquid solution. (14) A method of preparing a three-dimensional printed implanted object, comprising printing a printed structure using the ink of embodiment 10, drying the printed structure, and heat treating the printed structure. (15) The method of embodiment 14, wherein heat treating the printed structure comprises heating the printed structure such that the polymer is removed from the printed structure, and heating the printed structure to sinter the β-TCP or hydroxyapatite particles. (16) The method of embodiment 15, wherein the step of heat treating the printed structure comprises heating the printed structure from room temperature to 600° C. at a heating rate of 1° C. / min, heating the printed structure at 600° C. for 1 hour, heating the printed structure from 600° C. to 1140° C. at a rate of 5° C. / min, heating the printed structure at 1140° C. for 4 hours, and cooling the printed structure. (17) The method of embodiment 14, further comprising coating the printed structure with an anchorable protein by immersing the printed structure in a tBMP2 solution. (18) The method of embodiment 14, comprising combining the polymer solution with three or more solvents, wherein each of the solvents has a vapor pressure different from the vapor pressure of the other solvents. (19) The method according to embodiment 18, comprising the steps of: printing a printed structure using the ink according to embodiment 18; drying the printed structure to remove the first solvent; immersing the printed structure in a mixture of water and ethanol such that one of the second solvents is removed from the printed structure; and immersing the printed structure in a mixture of water such that one of the third solvents is removed from the printed structure.(20) A method for producing an ink for three-dimensional printing, comprising the steps of preparing a polymeric power mixture comprising tricalcium phosphate ceramic particles (β-TCP or hydroxyapatite), a biocompatible water-soluble polymer, and a biocompatible water-insoluble polymer, mixing the powder mixture by centrifugal mixing to at least partially melt the powder, and heating the powder mixture in the extruder chamber of a 3D printer to melt the powder prior to printing. (21) A method for preparing a three-dimensional printed implanted object, comprising the steps of printing a printed structure using the ink of embodiment 20, and immersing the 3D printed structure in water to remove the water-soluble polymer. (22) The method of embodiment 21, further comprising coating the printed structure with an anchorable protein by immersing the printed structure in a tBMP2 solution. (23) A method for treating a subject having a tissue defect, comprising: coating β-TCP or HA granules with tBMP2, mixing sodium carboxymethylcellulose hydrogel with the granules, mixing the mixture by centrifugal mixing to create a putty material, and surgically implanting the putty material into the tissue defect of the subject, thereby treating the subject. (24) A method for preparing a bone implant, comprising: forming an ink by mixing a photosensitive resin with β-TCP or HA particles, a photocurable acrylate, a plasticizer, a dispersant, a photoinitiator, and a light absorber, forming an implantable object with the ink, and coating the implantable object with an anchorable protein to form a bone implant. (25) The method of embodiment 24, further comprising heat treating the implantable object. (26) The method of embodiment 24, wherein forming the implantable object comprises digital light processing of the ink.

[0197] Other ways in which the utility of the present invention is demonstrated are by demonstrating bone regeneration in lumbar fusion indications (3D printed insert for spinal fusion cage), tibial segmental defects (3D printed scaffold based on patient CT data), and alveolar ridge augmentation (3D printed thin barrier membrane).

[0198] The terms used herein are intended to describe particular cases only and are not intended to limit the invention. The singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. To the extent that the terms "including," "includes," "having," "has," "with," or variations thereof are used in either the detailed description and / or claims, such terms are intended to be included in a manner similar to the term "comprising."

[0199] The term "about" or "approximately" means within an acceptable error range of a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, "about" can mean within 1 or more than 1 standard deviation, according to convention, for any value. When a particular value is described in the present application and claims, unless otherwise specified, the term "about" should be assumed to mean within an acceptable error range of the particular value.

[0200] As used herein, the term "subject" refers to any mammal. Thus, a subject may refer to, for example, a mouse, a rat, a dog, a cat, a horse, a cow, a pig, a guinea pig, a rat, a human, a monkey, etc. If the subject is a human, the subject may be referred to herein as a patient. In some embodiments, a subject or "subject in need of treatment" may be a canine (e.g., a dog), a feline (e.g., a cat), an equine (e.g., a horse), a sheep, a cow, a pig, a goat, a primate (e.g., a monkey (e.g., a marmoset, a baboon)), or an ape (e.g., a gorilla, a chimpanzee, an orangutan, or a gibbon), a human, or a rodent (e.g., a mouse, a guinea pig, a hamster, or a rat). In some embodiments, the subject or "subject in need of treatment" may be a non-human mammal, particularly a mammal traditionally used as a model to demonstrate therapeutic efficacy in humans (e.g., a murine, lagomorph, porcine, canine, or primate).

[0201] In some embodiments, the term "therapeutically effective amount" refers to an amount of a polypeptide or composition effective to "treat" a disease, illness, or condition in a subject. In some cases, a therapeutically effective amount of a polypeptide or composition reduces the severity of a symptom of a disease, illness, or disorder. In some instances, the disease, illness, or disorder includes an organ or tissue defect.

[0202] "Affinity" refers to the strength of the total non-covalent interactions between a β-TCP sequence (or a chimeric polypeptide or a polypeptide containing a β-TCP binding sequence) and its binding partner (e.g., β-TCP). Affinity can be measured by common methods known in the art, including those described herein. Affinity can be determined, for example, using surface plasmon resonance (SPR) technology (e.g., BIACORE®) or biolayer interferometry (e.g., FORTEBIO®). Additional methods for determining affinity are known in the art.

[0203] Percent (%) sequence identity to a reference polypeptide sequence is the percentage of amino acid residues in a candidate sequence that are identical to those in a reference polypeptide sequence, after aligning sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and does not consider any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be achieved in a variety of known ways, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Appropriate parameters for aligning sequences can be determined, including the algorithm required to achieve maximum alignment over the entire length of the sequences being compared. However, for the purposes herein, % amino acid sequence identity values ​​are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was created by Genentech, Inc., and the source code has been submitted to the U.S. Copyright Office (Washington DC, 20559) together with user documentation, and is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc. (South San Francisco, Calif.) or can be compiled from the source code. The ALIGN-2 program should be compiled for use on UNIX operating systems, including Digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

[0204] In situations where ALIGN-2 is used for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A to a given amino acid sequence B (which may alternatively be expressed as a given amino acid sequence A having or containing a % amino acid sequence identity to the given amino acid sequence B) is calculated as follows: multiply the fraction X / Y by 100, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in the sequences A and B of that program, and where Y is the total number of amino acid residues in B. It should be understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, then the % amino acid sequence identity of A to B is not equal to the % amino acid sequence identity of B to A. Unless otherwise specified, all % amino acid sequence identity values ​​used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

[0205] Each of the embodiments described and illustrated herein has distinct components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the invention. Any recited method may be carried out in the order of events recited or in any other order which is logically possible.

[0206] A number of embodiments of the present disclosure have been described. However, it is understood that various modifications may be made without departing from the spirit and scope of the present disclosure. For example, cells may be seeded into the implantable structure. These cells may include osteocytes or other bone cells, chondrocytes, and / or meniscus cells. In some instances, the cells may be added to the completed implantable structure. Additionally, although specific formulations for the inks have been described, variations in the specific amounts of each ink component are possible. Accordingly, other embodiments are within the scope of the following claims.

[0207] Embodiment Embodiment 1: A device comprising a therapeutic agent non-covalently bound to a printed three-dimensional structure, the printed three-dimensional structure comprising about 50% to about 100% by weight ceramic and about 0% to about 50% by weight polymer. Embodiment 2: The three-dimensional structure is approximately 1 g / cm 3 and about 3g / cm 3 Density between about 15% and about 45%, open porosity between about 0.50m 2 / g and about 1.0m 2 2. The device of embodiment 1, wherein the three-dimensional structure has a fiber diameter of about 325 μm and about 475 μm. Embodiment 3: The device of embodiment 1 or embodiment 2, wherein the ceramic comprises calcium phosphate, hydroxyapatite, fluorapatite, bone, silicate, or vanadate, or a combination thereof. Embodiment 4: The device of embodiment 1 or embodiment 2, wherein the ceramic comprises β-tricalcium phosphate (β-TCP). Embodiment 5: A device according to any one of embodiments 1-4, comprising a polymer, wherein said polymer comprises polycaprolactone. Embodiment 6: The device of embodiment 1 or embodiment 2, comprising about 100% by weight ceramic. Example 7: The device of embodiment 6, wherein the ceramic comprises β-tricalcium phosphate (β-TCP). Embodiment 8: The device of embodiment 1 or embodiment 2, comprising about 70% to about 80% by weight of ceramic and about 20% to about 30% by weight of polymer. Embodiment 9: The device of embodiment 8, wherein the ceramic comprises β-tricalcium phosphate (β-TCP) and the polymer comprises polycaprolactone. Embodiment 10: A device described in any one of embodiments 1-9, wherein the printed three-dimensional structure is formed from an ink comprising about 30% to about 70% by weight of ceramic, about 5% to about 30% by weight of polymer, and optionally an antifoaming agent and / or a dispersing agent. Embodiment 11: A device described in any one of embodiments 1-10, wherein the therapeutic agent comprises a mammalian growth factor or a functional portion thereof. Embodiment 12: A device according to any one of embodiments 1-10, wherein the therapeutic agent comprises one or more polypeptides selected from Table 4, or functional portions thereof. Embodiment 13: A device described in any one of embodiments 1-10, wherein the therapeutic agent comprises a bone morphogenetic protein (BMP). Embodiment 14: A device described in any one of embodiments 1-13, wherein the therapeutic agent comprises a targeting moiety, and the targeting moiety is non-covalently bound to the printed three-dimensional structure. Embodiment 15: The device of embodiment 14, wherein the targeting moiety is bound to the printed three-dimensional structure with an affinity of about 1 pM to about 100 μm. Embodiment 16: The device of embodiment 14 or embodiment 15, wherein the targeting moiety comprises a polypeptide at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to any one of the sequences in Tables 5-6. Embodiment 17: The device of embodiment 14 or embodiment 15, wherein the targeting moiety comprises about 2, 3, 4, 5, 6, 7, 8, 9, or 10 sequences selected from the sequences in Tables 5-6. Embodiment 18: A device described in any one of embodiments 1-17, wherein the therapeutic agent is a chimeric polypeptide comprising a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 794-802. Embodiment 19: A method of treating a disease in a subject in need thereof, the method comprising administering to the subject a device described in any one of embodiments 1-18. Embodiment 20: The method of embodiment 19, wherein the disease comprises bone defect, cartilage defect, soft tissue defect, tendon defect, fascial defect, ligament defect, organ defect, osteotendon tissue defect, skin defect, osteochondral defect, osteoporosis, avascular necrosis, or congenital skeletal deformity, or a combination thereof. Embodiment 21: The method of embodiment 19 or embodiment 20, wherein the method comprises spinal fusion. Embodiment 22: The method of embodiment 21, wherein the spinal fixation comprises posterolateral fixation (PLF) and / or interbody fusion. Embodiment 23: The method of embodiment 19 or embodiment 20, wherein the method comprises bone repair, dental repair, craniomaxillofacial repair, ankle fusion, vertebroplasty, osteoplasty, navicular fracture repair, tendon-bone repair, rib reconstruction, subchondral bone repair, cartilage repair, or surgical implantation of a three-dimensional structure or device, or a combination thereof. Embodiment 24: A method of producing a three-dimensional structure, the method comprising the steps of providing a solution comprising a ceramic, a polymer, and optionally an antifoaming agent and / or a dispersant, mixing the solution to obtain an ink formulation, and depositing the ink formulation in a three-dimensional form, wherein (i) the ink formulation comprises about 30% to about 70% by weight of ceramic and about 5% to about 60% by weight of polymer, and / or (ii) the three-dimensional structure comprises about 50% to about 100% by weight of ceramic and about 0% to about 50% by weight of polymer. Embodiment 25: The method of embodiment 24, wherein the ink formulation and / or the ceramic of the three-dimensional structure comprises calcium phosphate, hydroxyapatite, fluorapatite, bone, silicate, or vanadate, or a combination thereof. Embodiment 26: The method of embodiment 24, wherein the ink formulation and / or the three-dimensional structured ceramic comprises β-tricalcium phosphate (β-TCP). Embodiment 27: The method of any one of embodiments 24-26, wherein the polymer of the ink formulation comprises a first polymer comprising polycaprolactone and a second polymer comprising polyethylene glycol. Embodiment 28: The method of embodiment 27, wherein the ink formulation comprises about 10% to about 30% by weight of polycaprolactone and about 10% to about 30% by weight of polyethylene glycol. Embodiment 29: The method of any one of embodiments 24-28, wherein the three-dimensional structure comprises about 100% by weight of ceramic. Embodiment 30: The method of any one of embodiments 24-28, wherein the three-dimensional structure comprises about 100% by weight of β-tricalcium phosphate (β-TCP). Embodiment 31: The method of any one of embodiments 24-28, wherein the three-dimensional structure comprises about 70% to about 80% by weight of ceramic and about 20% to about 30% by weight of polymer. Embodiment 32: The method of any one of embodiments 24-28, wherein the three-dimensional structure comprises about 70% to about 80% by weight of β-tricalcium phosphate (β-TCP) and about 20% to about 30% by weight of polycaprolactone. Embodiment 33: The method of any one of embodiments 24-32, further comprising combining the three-dimensional structure with a therapeutic agent. Embodiment 34: The method of embodiment 33, wherein the therapeutic agent comprises a mammalian growth factor or a functional portion thereof. Embodiment 35: The method of embodiment 33, wherein the therapeutic agent comprises one or more polypeptides selected from Table 4, or functional portions thereof. Embodiment 36: The method of embodiment 33, wherein the therapeutic agent comprises a bone morphogenetic protein (BMP). Embodiment 37: The method of any one of embodiments 33-36, wherein the therapeutic agent comprises a targeting moiety that is non-covalently bound to said three-dimensional structure. Embodiment 38: The method of embodiment 37, wherein the targeting moiety binds to the printed three-dimensional structure with an affinity of about 1 pM to about 100 μM. Embodiment 39: The method of embodiment 37 or embodiment 38, wherein the targeting moiety comprises a polypeptide at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to any one of the sequences in Tables 5-6. Embodiment 40: The method of embodiment 37 or embodiment 38, wherein the targeting moiety comprises about 2, 3, 4, 5, 6, 7, 8, 9, or 10 sequences selected from the sequences in Tables 5-6. Embodiment 41: The method of any one of embodiments 33-40, wherein the therapeutic agent is a chimeric polypeptide comprising a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 794-802. Embodiment 42: A method of treating a disease in a subject in need thereof, comprising administering to the subject a three-dimensional structure produced by a method according to any one of embodiments 24-41. Embodiment 43: The method of embodiment 42, wherein the disease comprises a bone defect, a cartilage defect, a soft tissue defect, a tendon defect, a fascial defect, a ligament defect, an organ defect, an osteotendon tissue defect, a skin defect, an osteochondral defect, osteoporosis, avascular necrosis, or a congenital skeletal deformity, or a combination thereof. Embodiment 44: The method of embodiment 42 or embodiment 43, wherein the method comprises spinal fixation. Embodiment 45: The method of embodiment 44, wherein the spinal fixation comprises posterolateral fixation (PLF) and / or interbody fusion. Embodiment 46: The method of embodiment 42 or embodiment 43, wherein the method comprises bone repair, dental repair, craniomaxillofacial repair, ankle fusion, vertebroplasty, osteoplasty, navicular fracture repair, tendon-bone repair, rib reconstruction, subchondral bone repair, cartilage repair, or surgical implantation of a three-dimensional structure or device, or a combination thereof. Embodiment 47: An ink formulation for three-dimensional printing, the ink formulation comprising about 30% to about 70% by weight of a ceramic and about 5% to about 30% by weight of a polymer. Embodiment 48: The ink formulation of embodiment 47, wherein the ceramic comprises calcium phosphate, hydroxyapatite, fluorapatite, bone, silicate, or vanadate, or a combination thereof. Embodiment 49: The ink formulation of embodiment 47 or embodiment 48, wherein the ceramic comprises β-tricalcium phosphate (β-TCP). Embodiment 50: The ink formulation of any one of embodiments 47-49, comprising about 50% to about 70% by weight of ceramic, about 10% to about 30% by weight of a first polymer, and about 10% to about 30% by weight of a second polymer. Embodiment 51: The ink formulation of embodiment 47, comprising about 50% to about 70% by weight of β-tricalcium phosphate (β-TCP), about 10% to about 30% by weight of a first polymer comprising polycaprolactone, and about 10% to about 30% by weight of a second polymer comprising polyethylene glycol. Embodiment 52: An ink formulation according to any one of embodiments 47-49, comprising about 50% to about 70% by weight of ceramic, about 5% to about 15% by weight of polymer, and optionally an antifoaming agent and / or a dispersant. Embodiment 53: The ink formulation of embodiment 47, comprising about 50% to about 70% by weight of tricalcium phosphate, about 5% to about 15% by weight of a poloxamer, and optionally an antifoaming agent and / or a dispersing agent.

[0046] Embodiment 54: The ink formulation of embodiment 52 or embodiment 53, comprising about 0.1 wt. % to about 1 wt. % of an antifoaming agent, wherein the antifoaming agent optionally comprises an alcohol. Embodiment 55: The ink formulation of any one of embodiments 52-54, comprising about 0.1 wt.% to about 1 wt.% of a dispersant, wherein the dispersant optionally comprises an ammonium polyacrylate. Embodiment 56: An ink formulation according to any one of embodiments 47-49, comprising about 40% to about 60% by weight of ceramic, about 5% to about 15% by weight of polymer, and about 30% to about 40% by weight of solvent. Embodiment 57: The ink formulation of embodiment 47, comprising about 40% to about 60% by weight of β-tricalcium phosphate (β-TCP), about 5% to about 15% by weight of polycaprolactone, and about 30% to about 40% by weight of the solvent. Embodiment 58: The ink formulation of embodiment 56 or embodiment 57, wherein the solvent comprises dichloromethane, 2-butoxyethanol, dibutyl phthalate, or chloroform, or a combination thereof. Embodiment 59: A method for preparing a three-dimensional structure, said method comprising using an ink formulation as described in any one of embodiments 47-58 as an ink in a three-dimensional printing method. Embodiment 60: A three-dimensional structure prepared using an ink formulation according to any one of embodiments 47-58. Embodiment 61: The three-dimensional structure of embodiment 60, comprising about 50% to about 100% by weight of ceramic. Embodiment 62: The three-dimensional structure of embodiment 60, comprising about 50% to about 100% by weight of tricalcium phosphate. Embodiment 63: The three-dimensional structure described in embodiment 60, comprising about 50% to about 90% by weight of tricalcium phosphate and about 10% to about 50% of a polymer. Embodiment 64: The three-dimensional structure of embodiment 63, wherein the polymer comprises polycaprolactone. Embodiment 65: The three-dimensional structure has a mass of about 1 g / cm 3 and about 3g / cm 3 between about 15% and about 45% open porosity, and about 0.50m 2 / g and about 1.0m 2 65. The three-dimensional structure according to any one of embodiments 60-64, comprising one or more specific surface areas between about 325 μm and about 475 μm / g, wherein the three-dimensional structure has a fiber diameter of about 325 μm and about 475 μm. Embodiment 66: A three-dimensional structure comprising about 50% to about 100% by weight ceramic and about 0% to about 50% polymer. Embodiment 67: The three-dimensional structure of embodiment 66, wherein the ceramic comprises calcium phosphate, hydroxyapatite, fluorapatite, bone, silicate, or vanadate, or a combination thereof. Embodiment 68: The three-dimensional structure of embodiment 66 or embodiment 67, wherein the ceramic comprises β-tricalcium phosphate (β-TCP). Embodiment 69: The three-dimensional structure of embodiment 66 or embodiment 67, comprising about 50% by weight to about 100% by weight of ceramic. Embodiment 70: The three-dimensional structure of embodiment 66 or embodiment 67, comprising about 100% by weight of ceramic. Embodiment 71: The three-dimensional structure of embodiment 66, comprising about 100% by weight of tricalcium phosphate. Embodiment 72: The three-dimensional structure of embodiment 66 or embodiment 67, comprising about 50% to about 90% by weight of ceramic and about 10% to about 50% of polymer. Embodiment 73: A three-dimensional structure according to embodiment 66 or embodiment 67, comprising about 50% to about 90% by weight of tricalcium phosphate and about 10% to about 50% of a polymer. Embodiment 74: The three-dimensional structure of embodiment 72 or embodiment 73, wherein the polymer comprises polycaprolactone. Embodiment 75: The three-dimensional structure has a mass of about 1 g / cm 3 and about 3g / cm 3 between about 15% and about 45% open porosity, and about 0.50m 2 / g and about 1.0m 2 75. The three-dimensional structure according to any one of embodiments 66-74, comprising one or more specific surface areas between about 325 μm and about 475 μm / g, wherein the three-dimensional structure has a fiber diameter of about 325 μm and about 475 μm. Embodiment 76: A three-dimensional structure according to any one of embodiments 66-75, prepared by a three-dimensional printing method. Embodiment 77: A method for delivering a therapeutic agent to a subject in need thereof, the method comprising a step of delivering a device comprising the therapeutic agent and a three-dimensional structure described in any one of embodiments 60-76 to an organ or tissue of the subject. Embodiment 78: A device comprising a therapeutic agent and a three-dimensional structure described in any one of embodiments 60-76. Embodiment 79: The method according to embodiment 77 or the device according to embodiment 78, wherein the therapeutic agent comprises a mammalian growth factor or a functional portion thereof. Embodiment 80: The method according to embodiment 77 or the device according to embodiment 78, wherein the therapeutic agent comprises one or more polypeptides selected from Table 4, or functional parts thereof. Embodiment 81: The method of embodiment 77 or the device of embodiment 78, wherein the therapeutic agent comprises a bone morphogenetic protein (BMP). Embodiment 82: The method of any one of embodiments 77 or 79-81, or the device of any one of embodiments 78-81, wherein the device comprises a targeting moiety. Embodiment 83: The method according to embodiment 82 or the device according to embodiment 82, wherein the targeting moiety comprises a polypeptide comprising one or more sequences at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to any one of the sequences in Tables 5-6. Embodiment 84: The method according to embodiment 82 or the device according to embodiment 82, wherein the targeting moiety comprises about 2, 3, 4, 5, 6, 7, 8, 9, or 10 sequences selected from the sequences in Tables 5-6. Embodiment 85: The method according to any one of embodiments 82-84, or the device according to any one of embodiments 82-84, wherein the targeting moiety is non-covalently bound to the three-dimensional structure. Embodiment 86: The method according to any one of embodiments 82-85, or the device according to any one of embodiments 82-85, wherein the targeting moiety is connected to the therapeutic agent in the chimeric polypeptide. Embodiment 87: The method according to embodiment 86 or the device according to embodiment 86, wherein the chimeric polypeptide comprises a sequence at least about 70%, 75%, 80%, 85%, 90%, 95%, or 100% identical to any one of SEQ ID NOs: 794-802. Embodiment 88: A method for preparing a device described in any one of embodiments 78-87, the method comprising combining a therapeutic agent with a three-dimensional structure, wherein the therapeutic agent is non-covalently bound to the three-dimensional structure. Embodiment 89: A method for treating a disease in a subject in need thereof, comprising administering to the subject a three-dimensional structure described in any one of embodiments 66-76 or a device described in any one of embodiments 78 or 80-87. Embodiment 90: The method of embodiment 89, wherein the disease comprises a bone defect, a cartilage defect, a soft tissue defect, a tendon defect, a fascial defect, a ligament defect, an organ defect, an osteotendon tissue defect, a skin defect, an osteochondral defect, osteoporosis, avascular necrosis, or a congenital skeletal deformity, or a combination thereof. Embodiment 91: The method of embodiment 89 or embodiment 90, wherein the method comprises spinal fixation. Embodiment 92: The method of embodiment 91, wherein the spinal fixation comprises posterolateral fixation (PLF) and / or interbody fusion. Embodiment 93: The method of embodiment 89 or embodiment 90, wherein the method comprises bone repair, dental repair, craniomaxillofacial repair, ankle fusion, vertebroplasty, osteoplasty, navicular fracture repair, tendon-bone repair, rib reconstruction, subchondral bone repair, cartilage repair, or surgical implantation of a three-dimensional structure or device, or a combination thereof. Embodiment 94: The three-dimensional structure has a mass of about 1 g / cm 3 and about 3g / cm 3 The device according to any one of embodiments 1-18 or 78-87, the method according to any one of embodiments 19-46, 77, or 79-93, or the three-dimensional structure according to any one of examples 60-76, having a density between Embodiment 95: The device of any one of embodiments 1-18, 78-87, 94, the method of any one of embodiments 19-46, 77, or 79-94, or the three-dimensional structure of any one of examples 60-76, or 94, wherein the three-dimensional structure has an open porosity of between about 15% and about 45%. Embodiment 96: The three-dimensional structure is about 0.50 m 2 / g and about 1.0m 2 The device according to any one of embodiments 1-18, 78-87, 94, or 95, the method according to any one of embodiments 19-46, 77, or 79-95, or the three-dimensional structure according to any one of examples 60-76, 94, or 95, having a specific surface area of ​​between 100 nm and 100 nm / g. Embodiment 97: The device according to any one of embodiments 1-18, 78-87, or 94-96, the method according to any one of embodiments 19-46, 77, or 79-96, or the three-dimensional structure according to any one of examples 60-76, or 94-96, wherein the three-dimensional structure has a fiber diameter of about 325 μm and about 475 μm. Embodiment 98: The three-dimensional structure has a mass of about 1 g / cm 3and about 3g / cm 3 between about 15% and about 45% open porosity, and about 0.50m 2 / g and about 1.0m 2 The device according to any one of embodiments 1-18, 78-87, or 94-97, the method according to any one of embodiments 19-46, 77, or 79-97, or the three-dimensional structure according to any one of examples 60-76, or 94-97, wherein the three-dimensional structure has a specific surface area between about 325 μm and about 475 μm / g, and the three-dimensional structure has a fiber diameter of about 325 μm and about 475 μm. Embodiment 99: The three-dimensional structure has a mass of about 2.44 g / cm 3 The device of any one of embodiments 1-18, 78-87, or 94-98, the method of any one of embodiments 19-46, 77, or 79-98, or the three-dimensional structure of any one of examples 60-76, or 94-98, having a density of about 100% by mass, an open porosity of about 19.6%, and a fiber diameter of about 384 μm. Embodiment 100: The three-dimensional structure has a mass of about 1.32 g / cm 3 The device of any one of embodiments 1-18, 78-87, or 94-98, the method of any one of embodiments 19-46, 77, or 79-98, or the three-dimensional structure of any one of examples 60-76, or 94-98, having a density of about 100 μm, an open porosity of about 38%, and a fiber diameter of about 394 μm. Embodiment 101: The three-dimensional structure has a mass of about 1.49 g / cm 3 density, approximately 31% open porosity, 0.81m 2 The device according to any one of embodiments 1-18, 78-87 or 94-98, the method according to any one of embodiments 19-46, 77 or 79-98 or the three-dimensional structure according to any one of examples 60-76 or 94-98, having a specific surface area of ​​about 100 nm / g and a fiber diameter of about 420 μm. EXAMPLES

[0208] Example 1: Ink Formulation An ink formulation was prepared containing 60 wt% β-TCP powder (spray dried powder, 10-38 micron particle size), 20% polycaprolactone (50,000 MW, fine powder, Tmelt=60°C), and 20 wt% polyethylene glycol (1,500 MW flake, Tmelt=60°C). To make a 3.2 cc batch of ink, 2.062 g of β-TCP powder, 2.062 g of PCL powder, and 0.884 g of polyethylene glycol flake were added to a container. The container was placed in a mixer and the powders were mixed in a FlackTek Speedmixer at 300 rpm for 2 minutes to homogenize the powder blend. Higher rpm mixing was then performed at 3500 rpm for an additional 5 minutes to melt the powders. During this mixing, internal friction caused the PCL and polyethylene glycol to melt, which transformed the powder into a viscous molten liquid, which was used as input for the 3D fabrication of β-TCP / PCL structures.

[0209] Example 2: Manufacturing by 3D printing The ink of Example 1 was fabricated into structures using melt extrusion printing with an Allevi 3 Bioprinter. Briefly, the ink was loaded into a 5 cc stainless steel syringe with a 400 micron inner diameter conical metal luer lock tip. Prior to printing, the extruder chamber with the stainless steel syringe was heated to ensure melting of the ink. The ink was extruded using an extruder temperature of 120°C, a pressure of 70 psi, and a tip speed of 5 mm / s to 10 mm / s. The printed structures were immersed in distilled water overnight to dissolve the polyethylene glycol from the prints and create porous and flexible β-TCP / PCL structures.

[0210] The structure was examined using Brunauer-Emmett-Teller (BET) surface area analysis by gas physisorption. The surface area was 0.81 m 2 / g.

[0211] Compression tests were performed on the structure in a 1 cm diameter x 0.75 cm height cylinder. No fracture was observed at a strain of 33% and the structure elastically recovered to a strain of 10%. The elastic modulus was measured as 123 MPa ± 16 MPa.

[0212] Example 3: Therapeutic Agents A chimeric polypeptide comprising a BMP therapeutic peptide linked to five β-tricalcium phosphate binding peptides was expressed and purified using standard expression and purification methods. The chimeric polypeptide was called tBMP-2 and has the following sequence: MPIGSLLADTTHHRPWTVIGESTHHRPWSIIGESSHHKPFTGLGDTTHHRPWGILAESTHHKPWTASGAGGSEGGGSEGGTSGATGAGTSTSGGGASTGGGTGQAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR (SEQ ID NO: 434).

[0213] Example 4: Device Fabrication The structure of Example 2 was combined with the tBMP-2 therapeutic agent of Example 3 to create a device. A 0.75 mg / mL tBMP-2 binding solution (10 mM sodium acetate, 7 mM acetic acid, 100 mM NaCl, pH=4.75) was prepared and sterilized using a 0.22 μm filter. In a biosafety cabinet, 8 mL of tBMP-2 binding solution was added to a sterile 15 mL conical tube with a sterile pipette. The sterile scaffold from Example 2 was added to the binding solution with sterile tweezers, after which the conical tube was closed and wrapped in parafilm. The tube was placed on a LabLine Instruments Titer Plate Shaker, set to speed 2, and shaken for 2 hours. In a biosafety cabinet, the scaffold+tBMP-2 was removed using sterile tweezers and placed into a different sterile 15 mL conical tube filled with 8 mL of sterile PBS. The lid was closed, wrapped in parafilm, and placed back on the Titer Plate Shaker and shaken for 3 minutes at speed 2. The tube was opened in a biosafety cabinet and the scaffold+tBMP-2 was removed using sterile forceps and placed in a sterile petri dish. The scaffold+tBMP-2 was allowed to dry overnight in a biosafety cabinet, resulting in a tBMP-2 device. The tBMP-2 device is shown in FIG. 4A.

[0214] The mass of tBMP-2 remaining in the binding solution, and the mass of tBMP-2 in the PBS wash solution were measured using A280 absorbance measurements. The sum of these masses was calculated and then subtracted from the initial mass of tBMP-2 in the binding solution to obtain the mass of tBMP-2 that remained bound to the 3D printed scaffold. In this example, the scaffold has a tBMP-2 dose of 1.4 mg / cubic centimeter.

[0215] Example 5: Rabbit model of posterolateral (PLF) spinal fusion The purpose of this study was to compare the rate of fusion and the extent of new bone formation between autograft versus test article in a rabbit model of posterolateral (PLF) spinal fusion.

[0216] Rabbits were selected for this study because they are a commonly used species for nonclinical toxicity evaluation and evaluation of orthopedic implants, including spinal fusion applications. The FDA guidance document ("Class II Special Controls Guidance Document: Resorbable Calcium Salt Bone Void Filler Device, Guidance for Industry and FDA," US Food and Drug Administration, Center for Devices and Radiological Health, June 2, 2003) requires preclinical studies to support marketing applications. Rabbits are an approved species for spinal fusion testing according to ISO 10993-6, Annex D, and ASTM F3207-17-Standard Guide for In Vivo Evaluation of the Rabbit Lumbar Intertransverse Process Spinal Fusion Model. The total number of animals assigned to this study, as well as group size and number of groups, are the minimum required to adequately characterize the efficacy of the test material.

[0217] The test animals were New Zealand White female rabbits, approximately 6-7 months old and weighing approximately 3.5-5.0 kg at the time of surgery. The rabbits were acclimated to the facility for a minimum of 7 days and examined to ensure that they were free of clinical signs of disease.

[0218] Test materials The test material was the tBMP-2 coated device described in Example 4.

[0219] The rabbits were divided into two groups with three rabbits in each group: Group 1 was the autograft control and Group 2 received the test material.

[0220] 1. Preparation of Animals before Surgery A fentanyl transdermal patch (25-1.1 g / hr) was applied to the animals prior to surgery. Anesthesia induction was initiated by intramuscular injection of acepromazine (0.25-0.75 mg / kg) and butorphanol (approximately 0.5 mg / kg). An intravenous catheter was placed in the marginal ear vein, and general anesthesia was induced using propofol (5-7 mg / kg) IV to achieve this. After induction of anesthesia, an endotracheal tube was inserted and anesthesia was maintained using isoflurane in oxygen (0.5-4% until effective). Perioperative cefazolin (approximately 40 mg / kg) was administered intravenously during preoperative preparation. Ophthalmic ointment was administered to the eyes to prevent corneal drying. Preoperative radiography was used to image the lumbar spine and mark the location of L4 and L5. The dorsal lumbosacral area was excised and prepared for aseptic surgery by scrubbing with povidone-iodine antiseptic solution followed by three repeated washes with 70% isopropyl alcohol. The area was smeared with povidone-iodine solution and draped for aseptic surgery. The animal was transferred to the operating room, placed on a heated operating table, connected to an anesthesia machine and monitor, transferred to the operating room, and draped for aseptic surgery. Lactated Ringer's solution was administered intravenously during surgery at approximately 10 ml / kg / h. While under general anesthesia, the animal was monitored by trained personnel who assessed and documented heart rate, respiratory rate, and oxygen saturation percentage every 10 to 15 minutes.

[0221] Surgery procedure Autograft harvest: A midline skin incision was made over the caudal lumbosacral spine to access the L4-5 gap and iliac crest. Ropivacaine or other topical analgesic was infiltrated into the soft tissue adjacent to the crest to provide local analgesia. Approximately 3 cc of iliac crest bone graft (ICBG) was harvested using an osteotome, curette, and rongeur and divided into small irregularly sized particles up to 4 mm in diameter. ICBG was harvested bilaterally from Group 1 animals and loaded into two open barrel 3 cc syringes.

[0222] Spinal fusion: A paraspinal incision was made in the fascia above the L4-L5 gap and the seam between the paraspinalis and multifidus muscles was identified and separated by blunt dissection. The dorsal surface of the L4 and L5 transverse processes was exposed bilaterally by elevating and retracting the soft tissue. Pressure and focal electrocautery were used to control bleeding as needed. A motorized burr was used to decorticate approximately 2 cm of the dorsal surface of the L4 and L5 transverse processes adjacent to the lamina but not extending onto the pars. The implant was placed in contact with and spanning the distance between the two sides of the decorticated L4 and L5 transverse processes. The surgical incision was closed in three layers following standard surgical techniques. See Figure 4D.

[0223] Animal care Animals were observed at least twice daily for three days after surgery to assess recovery from anesthesia, appetite, and analgesia. Thereafter, animals were observed twice daily for general health and well-being and recovery of appetite until they were able to eat normally. Thereafter, animals were observed every morning for general health and well-being, with a cursory check in the afternoon. Rabbits were weighed to monitor general health at the time of staple removal approximately 7-10 days after surgery, and at approximately 2-week intervals throughout the study period.

Claims

1. A device comprising a three-dimensional structure, a therapeutic agent, and a targeting moiety, wherein said targeting moiety is a polypeptide linked to said therapeutic agent in a chimeric polypeptide and non-covalently bound to said three-dimensional structure; the three-dimensional structure comprises a ceramic and optionally a polymer; the ceramic is present in the three-dimensional structure at 50% to 100% by weight; The polymer is present in the three-dimensional structure at 0% to 50% by weight. device.

2. The device of claim 1 , wherein the ceramic is present in the three-dimensional structure at 50% to 70% by weight and the polymer is present in the three-dimensional structure at 5% to 30% by weight.

3. 3. The device of claim 1 or claim 2, wherein the ceramic comprises calcium phosphate, hydroxyapatite, fluorapatite, bone, silicate, or vanadate, or a combination thereof.

4. The device of any one of claims 1 to 3, wherein the ceramic comprises β-tricalcium phosphate (β-TCP).

5. The device of claim 1 , comprising the polymer, wherein the polymer comprises polycaprolactone.

6. The device of claim 1, comprising 100% by weight ceramic.

7. The device of any one of claims 1 to 6, comprising the polymer, wherein the ceramic comprises β-tricalcium phosphate (β-TCP) and the polymer comprises polycaprolactone.

8. The three-dimensional structure has a density of 1 g / cm 3 to 3 g / cm 3 The device according to claim 1 , having a density of

9. 9. The device of claim 1, wherein the three-dimensional structure has an open porosity of between 15% and 45%.

10. 10. The device of claim 1, wherein the three-dimensional structure comprises fibers having diameters of 325 μm and 475 μm.

11. The device of claim 1 , wherein the therapeutic agent comprises a mammalian growth factor or a functional portion thereof.

12. The device of any one of claims 1 to 11, wherein the therapeutic agent comprises a bone morphogenetic protein (BMP).

13. 13. A device according to any one of claims 1 to 12 for use in a method for treating a disease comprising a bone defect, a cartilage defect, a soft tissue defect, a tendon defect, a fascial defect, a ligament defect, an organ defect, an osteotendinous tissue defect, a skin defect, an osteochondral defect, osteoporosis, avascular necrosis, or a congenital skeletal deformity, or a combination thereof.

14. The device of claim 13, wherein the method comprises spinal fusion, bone repair, dental repair, craniomaxillofacial repair, ankle fusion, vertebroplasty, osteoplasty, navicular fracture repair, tendon-bone repair, rib reconstruction, subchondral bone repair, or cartilage repair.

Citation Information

Patent Citations

  • Porous beta-tricalcium phosphate granules and method of producing the same

    JP2005505311A

  • Porous ceramic composite bone graft

    JP2005512614A

  • Tricalcium Phosphate, Composites Thereof, Implants Incorporating Them and Methods of Making Them

    JP2007503849A

  • Biological material and method for producing biological material

    JP2008142379A

  • Bone putty

    JP2014528734A